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ABSTRACT  
 
Dinuka M. De Silva: Role of Androgen Receptor Co-repressor SLIRP in Cell Cycle regulation 
(Under the direction of Young E. Whang) 
 
Androgen receptor (AR) reactivation is a hallmark of castration resistant prostate cancer 
(CRPC). One mechanism is tyrosine kinase Ack1 mediated activation phosphorylation of Tyr-
267 and Tyr-363 residues on AR. Investigation into Ack1 regulation of AR identified SLIRP as a 
potential AR interacting protein. SLIRP acts as a co-repressor of steroid receptor signaling. We 
show that SLIRP interacted with AR in the absence of Ack1 activation, repressing AR signaling. 
In the presence of either androgen or Ack1 kinase activation, SLIRP dissociated from the 
complex and AR signaling was activated. SLIRP dissociation from AR was dependent on the 
kinase activity of Ack1 but not the known Ack1 phosphorylation sites of Tyr-267 and Tyr-363 of 
AR. Furthermore, SLIRP-AR binding was dependent on RNA co-regulator SRA in AR signaling 
as knockdown of SRA resulted in reduced SLIRP co-immunoprecipitation with AR. 
 Microarray and RNA-seq gene expression profiling of LNCaP cells with SLIRP 
knockdown generated a large gene list. One major affected pathway was the cell cycle pathway. 
LNCaP and LAPC4 cells treated with SLIRP siRNA demonstrated increased phosphorylation of 
Rb protein, enhanced cell proliferation, and increases in CDK1 and CDK6, cyclins E1, A2, and 
E2F1 and E2F2 mRNA levels. In addition, cell cycle analysis demonstrated an increased number 
of cells in S-phase with SLIRP knockdown, compared to control. Investigation of other known 
AR co-repressors, NCoR1 and SMRT, did not demonstrate a similar role in cell cycle. However,
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knockdown of co-repressor SHARP showed an effect on cell cycle by increased phospho-Rb 
protein and S-phase entry, but to a lesser extent than SLIRP. AR negative PC3 and DU145 cells 
did not recapitulate the results in LNCaP cells, suggesting AR dependence in the role of SLIRP 
in cell cycle. 
In conclusion, we define a novel mechanism in which AR activity is regulated by SLIRP 
binding that is disrupted by Ack1 kinase or androgen. Ack1 gene amplification or AR mutations 
seen in CRPC may confer sensitivity of AR to low levels of androgens. Hence, our data suggests 
that disruption of SLIRP repression of AR-dependent transcription may be a potential 
mechanism of inappropriate restoration of AR signaling in CRPC. 
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CHAPTER I: INTRODUCTION 
1.1 Prostate Cancer Epidemiology 
Cancer is a predominant public health problem around the world. For men, prostate 
cancer accounts for 241,740 new cases a year with 28,170 deaths in the United States [1]. 
Despite significant research efforts, death rates for men with prostate cancer has stayed fairly 
constant from 1930-2008[1]. Risk factors for prostate cancer depend on age, family history, and 
race or ethnicity [2].  For example, according to National Cancer Institute’s Surveillance, 
Epidemiology, and End Results (SEER) Program, African Americans have a higher incidence 
and mortality of prostate cancer than Caucasians [2, 3]. Other ethnic groups including Asian 
American men, American Indian and Alaskan Native men (AI/AN) and Hispanic men have a 
lower prostate cancer incidence and mortality rate compared to European American men (EAM) 
(American Cancer Society, 2007).  
While the 5 year relative survival rates have increased with a shift towards more localized 
disease[3], men with metastatic disease have a much lower 5 year survive rate [3]. Particularly, 
age is the distinguishing feature of detectable prostate cancer as men are not diagnosed until in 
their 60’s. The probability of developing invasive prostate cancer is 6.84% (1 in 15) for men 60-
69 yrs old [1].  Heredity factors account for 5-10% of prostate cancer and are related to an earlier 
onset of the disease [4]. Families with 1 first degree member has a 2.5 fold increased risk of 
disease while 2 first degree members gives an individual in the family a 5-fold increased risk [5]. 
Recent research suggests that multiple genes may interact with environmental factors to increase 
the risk of prostate cancer instead of a small subset of genes [6, 7]. Familial susceptibility loci 
have been mapped to the X chromosome and region of chromosome 1q [4]. Furthermore, linkage 
mapping studies also identified susceptibility to PCa on chromosome 8, 10, 16, 17, and 20 and 
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candidate genes HPC1 on chromosome 1q23-25, PCAP on chromosome 1q42-43, and CAPB on 
chromosome 1p36 [7]. In addition, trinucleotide repeats encoding polyglutamine (CAG)n and 
polyglycine (GGN)n in the androgen receptor exist whose polymorphisms are associated with 
increased risk of PCa [8]. Interestingly, the frequency of (CAG)n repeats were higher in African 
American males compared to European and Asian but did not associate with increased PCa risk 
[9, 10]. A polymorphism in CYP17, an enzyme important in the synthesis of adrenal and 
intratumoral androgen synthesis, may be associated with susceptibility to PCa in men of African 
but not European descent [11]. 
Diet and life style can also influence risk for prostate cancer development. The 
distribution of PCa incidence and mortality rates among different geographical locations in the 
world demonstrates a difference in distribution. Eastern countries like China and Japan have 
historically lower incidence of PCa than in the United States and the Caribbean [7, 12]. An 
association also exists between the high consumption of red meat, saturated fat, and dairy 
products and PCa pathogenesis [6, 7]. Thus, the higher rate of PCa incidence in the U.S could be 
related to be a higher intake of animal protein than in Asian countries [13, 14]. Hence, we must 
appreciate the environmental and dietary factors that play a role in the increased risk of prostate 
cancer, particularly in the western world. 
1.2 Natural history of PC 
The prostate glands surround the urethra at the base of the bladder. The glands are lobular 
with ductal-acinar histology and functions in the secretion of proteins to the seminal fluid. The 
human prostate contains 3 distinct regions, the peripheral zone, the transition zone, and the 
central zone. On the other hand, the rodent prostate contains 4 lobes, anterior, dorsal, lateral, and 
the ventral. Non-malignant benign prostate hyperplasia (BPH) arises in the transition zone while 
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prostate carcinoma arises in the peripheral zone [15]. The epithelial and mesenchymal interaction 
is important in prostate gland development as prostatic differentiation requires both components 
and in absence of either, the cells fail to differentiate [4]. Furthermore, androgen is required in 
the mesenchyme to produce signals for prostate development and growth and later in the 
epithelium for secretory function [4].  Secretory luminal cells, stem cell like basal cells, and the 
neuroendocrine cells make up the prostatic duct. Luminal cells express androgen receptor 
important in prostate carcinoma and are further characterized by the expression of cytokeratins 8 
and 18 and CD57[4].  
Initiation of progression of normal epithelium of the prostate to prostatic intraepithelial 
neoplasia (PIN) is marked by inflammation, oxidative stress, telomere shortening and changes in 
genes like NKX3.1, Myc, and TMPRSS2-ERG fusion [16]. PIN is characterized by luminal 
epithelial hyperplasia, a reduction in basal cells, cytoplasmic hyperchromasia, and nuclear atypia 
[16]. Furthermore, in high-grade PIN there is an increase in cell proliferation markers [17]. 
Progression from PIN to adenocarcinoma is marked by re-activation of signaling pathways 
including ERK/MAPK and androgen receptor (AR) pathways. Transition between 
adenocarcinoma to metastasis is indicated by the development of castration resistant tumor and 
epithelial to mesenchymal transition (EMT) [16]. Though prostate adenocarcinoma lacks distinct 
subtypes, there are occurrences of ductal adenocarcinoma, mucinous carcinoma, and signet ring 
carcinoma although rare [18]. Metastasis of prostate cancer is primarily to bone and lymph 
nodes. Circulating tumor cells could be detected in the bone marrow of patients with localized 
disease and in metastatic disease [19]. 
There is no perfect model in prostate cancer especially since rodents do not develop 
prostate cancer. In order to reliably target expression of genes within the prostate, the rat 
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probasin (PB) promoter is used. The construction of the promoter includes using two consensus 
AR binding sites within the promoter (2236 to 2223 and 2140 to 2117), known as the androgen 
response region (ARR) [20]. A better version of this promoter was generated by using a larger 
region of the probasin promoter (LPB) with 2 ARR regions called ARR2PB which maintains 
reliable prostate specificity but also provides very high transgene expression in transgenic mice 
[20]. Subcutaneous and orthotopic xenografts use immune compromised mice to facilitate tumor 
growth. Other models include genetically engineered mouse models (GEMMs) with germ-line 
knockout of important cancer genes like PTEN and NKX3.1 and SV40 transgene expression 
GEMMS including TRAMP and LADY. PTEN is a tumor suppressor gene whose inactivation is 
seen in 35% of metastatic tumors [21]. Half of heterozygotes develop multi-focal PIN and 
carcinogenesis [20]. Homozygosity of the null mutation results in embryonic lethality and PTEN 
heterozygotes fail to develop metastasis [21]. NKX3.1 is involved in early embryonic patterning 
and organogenesis, epithelial proliferation and is important in recognition of PIN development as 
noted previously. NKX3.1 null mutations disrupt normal prostate protein secretion and ductal 
morphogenesis and have become a model for PIN [22]. Though this model is good for early 
progression of prostate cancer, it fails to develop invasive carcinoma. The TRAMP (transgenic 
adenocarcinoma of the mouse prostate) model uses the expression of both the large and small 
SV40 tumor antigens regulated by the rat probasin promoter. TRAMP mice develop PIN by 18 
weeks and lymphatic metastases after 28 weeks [23]. Although GEMMs rarely portray 
metastasis to the bone, it was the first model to show castration-resistant tumor development 
[23]. One flaw with this model is that the most frequent malignancy arises from neuroendocrine 
cells whereas human prostate adenocarcinoma generally come from epithelial cells [23]. The 
LADY model is similar to TRAMP except it uses the second generation probasin promoter 
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(LPB)  to drive expression of a deletion mutant of the SV40 T antigen that expresses only the 
large T antigen [23]. While this model can be used to study the progression from hyperplasia to 
adenocarcinoma, it does not model castration resistance and metastasis [23]. 
1.3 Prostate Cancer Therapy 
Prostate cancer is dependent on androgens for metastatic progression. Thus, androgen 
deprivation therapy (ADT) carried out by either surgical or chemical castration is applied to 
patients with metastatic disease (Fig 1.1) [24]. Chemical castration involves luteinizing 
hormone-releasing hormone (LH-RH) analogs or LHRH antagonists. LHRH agonists decrease 
androgens generated by the testicles and include drugs leuprolide, goserelin, triptorelin, and 
histrelin. However, LHRH agonists initially stimulate pituitary LHRH receptors which induces 
an increase in LH and FSH release that increases testosterone levels[25]. This is termed a 
testosterone “flare” and can exacerbate bone pain in advanced patients [25]. LHRH antagonists 
work similarly to the agonists but do not produce the “flare” and include degarelix and abarelix. 
Unfortunately, within 18-24months, patients become terminal due to development of castration 
resistant prostate cancer (CRPC) from ADT in part due to AR reactivation (Fig 1.1).  
Surgery, cryosurgery, brachtherapy, high intensity focused ultrasound, external beam 
radiation therapy (EBRT), high-intensity focused ultrasound radio frequency, interstitial ablation, 
and others are used to treat localized prostate cancer. Surgery and EBRT are the mainstream 
options for treating localized prostate cancer. Patient selection is determined by the ability to do 
pre-operative mapping of tumor lesions that can be complicated by the multi-focality and 
histologically heterogeneous nature of the tumors. Low risk patients with clinical T1 and T2 
disease with PSA≤ 10 ng/ml and Gleason score ≤ 6 are at a lower probability of cancer 
recurrence compared to high risk patients. External beam radiation therapy (EBRT) uses high 
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energy photon field in precisely defined locations in the prostate. EBRT uses computer generated 
tomographic images of a patient’s anatomy to identify these locations. Brachytherapy (seed 
implant therapy) is a cancer treatment with ionizing radiation delivered via radioactive material 
placed near or within the tumor.  
Disease progression at the CRPC stage is due to many factors including hypersensitivity 
to low levels of androgens, AR gene amplification, AR mutations, regulation of co-repressors 
and co-activators, growth factors, and activation by tyrosine kinases [26-29]. First generation 
anti-androgens nilutamide, flutamide, and bicalutamide have a modest affect when combined 
with medical or surgical castration but there is little clinical evidence of benefit with relapsed 
patients [30-32]. Current standard first line therapy for CRPC is docetaxel. Docetaxel induces an 
apoptotic affect by inhibiting microtubule dynamics leading to mitotic arrest. In the TAX327 
trial, patients with metastatic CRPC (mCRPC) were treated with prednisone and randomized to 
docetaxel 75 mg/m2 intravenously every 3 weeks, docetaxel 30 mg/m2 weekly for 5 of 6 weeks, 
or mitoxantrone 12 mg/m2 intravenously every 3 weeks[33]. Patients treated with every 3-week 
docetaxel had better PSA response rates, pain reduction, and quality-of-life measures, and 
median survival of 19.2 months compared to 16.3 months with mitoxantrone [33]. Toxicities of 
docetaxel treatment include fatigue, hematologic toxicity, and neurotoxicity and thus require 
treatment breaks or discontinuation.  
The new generation of therapeutics includes cabazitaxel which inhibits microtubule 
depolymerization and cell division, abiraterone that targets adrenal androgens, and AR 
antagonist MDV3100 among others (Fig 1.2). Cabazitaxel is a semisynthetic taxane which has 
poor affinity for P-glycoprotein-1, an ATP-dependent drug efflux pump. A phase III TROPIC 
study of mCRPC patients with progressive disease following docetaxel treatment compared 
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prednisone with either cabazitaxel or mitoxantrone [34]. There was improved overall survival of 
CRPC patients compared to mitoxantrone (15.1 months vs. 12.7months) and has been approved 
by the FDA [34, 35].  Adverse side effects included hematologic, infectious, and gastrointestinal 
toxicity. Abiraterone is an adrenal inhibitor of CYP17, a cytochrome p450 complex involved in 
adrenal steroidal synthesis as well as intratumoral androgen synthesis [35]. CYP17 catalyzes the 
conversion of pregnenolone and progesterone to dehydroepiandrosterone (DHEA) and 
androstenedione. Abiraterone is given with prednisone due to the mineralocorticoid excess that 
results in hypertension, hypokalemia, and edema. Two phase II studies of patients pretreated 
with docetaxel and than abiraterone illustrated a greater than 50% decline in PSA in 36% and 
51% of patients respectively [36, 37]. A phase III study investigating abiraterone plus prednisone 
compared with prednisone alone showed prolonged survival of CRPC patients who had disease 
progression after docetaxel [38]. Overall survival was greater in patients treated with abiraterone 
plus prednisone than with placebo plus prednisone (14.8 months vs. 10.9 months) [35, 38]. 
Enzalutamide (MDV3100) has greater affinity for AR, lacks agonist effects unlike bicalutamide, 
inhibits ligand binding to AR, and inhibits AR nuclear translocation [39]. A phase III study, the 
AFFIRM trial, investigated 1,199 men with docetaxel-treated CRPC that received oral 
enzalutamide 160 mg once daily or placebo [40]. They demonstrated that enzalutamide improved 
overall survival and reduction of the risk of death by 37% compared to control group [40]. The 
phase III trial indicated that the median survival for patients treated with MDV3100 was 18.4 
months compared with 13.6 months for placebo group [35, 40]. Since the results of this study, 
the FDA has approved enzalutamide for CRPC patients who have been treated with 
chemotherapy. While these different clinical studies show a broad range of survival times for 
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similar populations, they may reflect differences in the stage of migration, disease management, 
and new emerging therapeutics [41].  
1.4 AR genomics 
Androgens are the main sex steroids important in male sexual differentiation, maturation 
during puberty, and development of prostate cancer. Androgens also play a role in non-
reproductive tissues such as skin, bone, muscle, and brain [42]. Androgens, testosterone (T) and 
the more potent form, 5α-dihydrotestosterone (DHT) are the ligands for AR. The human AR 
gene located on chromosome Xq11-12 consists of 8 known exons which encode a ~110 kDa 
protein. Androgens and AR may also play a role in female reproduction as AR knockout in 
female mice leads to ovarian dysfunction [43]. Androgen receptor plays an essential role in all 
aspects of prostate tumorigenesis. 
 Androgen receptor consists of a N-terminal activating domain, DNA binding 
domain, a hinge region, and a C-terminal ligand binding domain (Fig 1.3) [27]. Additional 
analysis revealed two transcriptional activation functional domains, AF-1 in the N-terminus 
(ligand-independent) and AF-2 in the C-terminus (ligand-dependent) (Fig 1.3) [28]. AR has two 
isoforms, an ~87 kDa protein (AR-A) where the N-terminus is truncated (lacks the first 187 
amino acids) and the full length 110kDa AR [44]. AR is located in the cytoplasm in an inactive 
conformation bound by chaperone proteins like heat shock proteins (HSP). AR can be activated 
by androgens where binding in the cytoplasm results in the translocation of AR to the nucleus 
while simultaneously it is bound and unbound by varying chaperone proteins [28, 45]. AR 
translocates into the nucleus where it forms a homodimer and binds androgen-response elements 
(AREs) located in the regulatory regions of the target genes [3, 5].  
  
  9 
 Mechanisms of AR activation in CRPC consist of AR gene amplification, AR 
mutations, splice variants, ligand-independent activation by growth factors, kinase activation, 
and co-regulator changes. There is a continued reliance on AR for the progression and metastasis 
of prostate cancer. More than 50% of CRPC tumors have some AR alterations. AR gene 
amplification occurs in 30% of CRPC tumors while 10-20% will have an AR mutation [46]. For 
example, in the well used LNCaP prostate cancer cell line, there is a missense mutation at codon 
877 that changes the amino acid from threonine to alanine (T877A) [46]. This mutation in the 
ligand binding domain leads to decreased ligand specificity where other hormone like 
progesterone and estrogens can bind and activate AR [46]. Another important mutation is the 
gene fusion of androgen dependent TMPRSS2 and Ets transcription gene ERG. TMPRSS2-ERG 
plays a role in early tumor development. It is expressed in pre-neoplastic lesions and 50% of 
primary PC as well as 30% of CRPC [47, 48]. Since the discovery of TMPRSS2-ERG fusion, 
many others have come to light including TMPRSS2–ETV1, NDRG1–ERG, and TMPRSS2–
FKBP5–ERG which are regulated by androgen and/or androgen receptor [48]. 
Co-activators like TIF1/SRC1 (aka KAT13A, RIP160, bHLHe42, bHLHe74), 
TIFII/Grip1 (aka SRC2, KAT13C; NCoA2, bHLHe75), and SRC3 (aka ACTR, AIB1, RAC3, 
pCIP, CTG26, CAGH16, KAT13B, TNRC14, TNRC16, TRAM-1, bHLHe42) which are part of 
the SRC/p160 family and the ARA family all modulate AR activity. ARA70 binding to AR can 
enhance transcriptional activity 5-10 fold at low levels of androgens and in the presence of anti-
androgens like hydroxyflutamide [49]. SRC-1, CBP/p300, and p300/CBP-associated factor 
modulate AR via their histone acetyltransferase activity and thus remodel chromatin structure 
[46]. Furthermore, copy-number gain in the SRC-2 gene (also known as NCoA2/TIF2/GRIP1) 
plays an important role in AR activation in CRPC [50]. In 17% of tumors, there were broad gains 
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of the region spanning SRC-2 and 6.2% had high level amplification of the locus [50]. Taylor et 
al 2010 showed that overall, 8% of primary tumors and 37% of metastases had SRC-2 gain of 
expression or mutations [50]. On the other hand, co-repressors that inhibit transcription of AR 
dependent genes include NCoR1 and SMRT. These well known co-repressors can bind AR 
directly as well as recruit HDACs’ to promote chromatin packing and inhibit transcription.  
Growth factors also play a role in aberrant AR signaling. Epidermal growth factor (EGF) 
is a growth factor that stimulates cell proliferation and differentiation by binding to epidermal 
growth factor receptor (EGFR). EGF and its receptor EGFR have increased expression in 
prostate metastatic disease [51]. EGFR activation can lead to activation of the MAPK pathway 
down-regulating AR and relieving AR inhibition of cell cycle in differentiated cells [51, 52]. 
Conversely, EGF stimulation of LNCaP cells induces phosphorylation of AR at Tyr-267 and 
Tyr-534 by Src and Ack1 kinases inducing AR activation [53]. EGF also leads to increased 
levels of STAT3 that results in the formation of a STAT3-AR complex and increased 
transcriptional activity [51].  
1.5 AR and Cell cycle 
There exists a dynamic relationship between AR, androgens and cell cycle (Fig 1.4). 
Androgens can stimulate cell cycle and thus enhance cell proliferation by upregulating cyclins 
and cyclin dependent kinases (CDK) which control progression of cell cycle phases. 
Consequently, the up-regulation of cyclins and CDKs can result in inhibition of AR. Cells in 
resting phase, G0, are regulated by the retinoblastoma protein (Rb) to prevent unplanned cell 
cycle progression by assembling transcriptional repressor complexes that prevent E2F1-DP1 
from facilitating G1 to S-phase transition [54].  Activation of mitogenic signaling results in 
cyclin D1 accumulation and subsequent binding to CD
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phosphorylation of Rb and partial inactivation. Complete inactivation of Rb is produced when 
other CDKs like CDK1 and CDK2 interact with cyclin B, A, and E (Fig 1.4).  
 Androgen is a regulator of G1-S phase transition where androgen deprivation 
results in G1 arrest, Cyclin D1 and D3 loss, and hypophosphorylated Rb [55, 56]. Furthermore, 
cyclin A, a target of Rb-mediated transcriptional repression, and CDK2 activity is reduced with 
androgen depletion [57]. Low p27/Kip1 expression can be a marker of short time to recurrence and 
androgen deprivation can induce p27Kip1 which contributes to CDK2 reduction [55, 58]. p21/Cip1 
is a direct AR target and is lost with androgen deprivation in vitro [55, 59]. Conversely, AR can 
be regulated by the cell cycle. For instance, cyclin D1 can bind directly to N-terminus of AR and 
block conformational change for maximal AR activity [60, 61]. Thus, cyclin D1 acts as a 
negative feedback regulator of AR suppressing activity and androgen-dependent proliferation. 
CDK6 was shown to bind AR and act as a co-activator (independent of cyclin D1) that enhances 
growth and PSA gene expression [62]. Similarly, cyclin E behaves like CDK6 by binding and 
enhancing AR activity independent of CDK2 binding [63]. Furthermore, activated CDK1 
enhances stability and transcriptional activity of AR [64]. Analysis of PCa tumor samples that 
relapsed after androgen deprivation therapy, demonstrated high over-expression of cyclin B1,B2, 
CDK1, Ccd25B, and Cdc25c (mediates activation of CDK1) [65, 66]. Notably, it was found that 
AR transcriptional activity is reduced at the G1/S transition and regained during S-phase [67]. In 
addition, AR can interact with the pre-replication complex (pre-RC) to augment LNCaP cells 
from G1 to S phase [68]. A critical balance exists where androgen/AR activation can enhance 
cell cycle regulators and in turn those same regulators mediate AR activity. 
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1.6 Ack1 in Prostate Cancer 
There are ten families of non-receptor tyrosine kinases which involve Src, Abl, Jak, Ack1, Csk, 
Fak, Fes, Frk, Tec, and Syk. Ack1 or Tnk2 is a 120 kDa intracellular non-receptor tyrosine 
kinase comprising of an N-terminal tyrosine kinase domain, a SRC homology 3 domain, a 
cdc42/Rac interactive binding domain (CRIB), and a C-terminal proline rich domain (Fig 1.5) 
[69]. Ack1 was cloned from a human hippocampal expression library by its ability to bind 
activated GTP bound cdc42 and not Rac1 or RhoA [69]. Ack1 gene is located on chromosome 
3q29, a region linked to prostate cancer recurrence [70]. Advanced stage primary tumors and 
metastatic tumors contain copy number gain of the ACK1 gene as well as overexpression of 
ACK1 mRNA [70]. Ack1 overexpression was found in 10 of 13 hormone refractory prostate 
cancer tumor samples but rarely in early stage primary tumors (1 of 53) [70]. Ack1 is expressed 
in various tissues with highest expression in brain, spleen, and thymus [71]. Factors that activate 
Ack1 include EGF, platelet derived growth factor (PDGF), and bradykinin. EGF activation of 
EGFR leads to Ack1 autophosphorylation which in turn can activate the guanine nucleotide 
exchange factor Dbl leading to actin cytoskeletal rearrangements [72]. Furthermore, EGF 
stimulation also leads to interaction of Ack1 with adaptor protein Grb2 which leads to interaction 
with receptor tyrosine kinases Axl, leukocyte tyrosine kinase (LTK), and anaplastic lymphoma 
kinase (ALK) [73]. EGFR is regulated by Ack1 interaction with various partners including 
ubiquitin, clathrin heavy chain, and sh3px1 [74]. Ack1 degradation is mediated by the E3 
ubiquitin ligase Nedd4-2 via a PPY motif [75]. EGFR activation of Ack1 drives Nedd4-2 kinase 
degradation [75].Ack1 co-localizes with Nedd4-2 in clathrin-rich vesicles [75].  
  Ack1 is important in cell migration, adhesion, and cell spreading. Ack1 has been 
shown to complex with Cas, Crk, and cdc42 to mediate cell migration. Cdc42 activation of Ack1 
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mediates phosphorylation of p130cas which promotes cell migration [76]. A cdc42-Ack1-Cas 
complex is also involved in the regulation of melanoma cell spreading by melanoma chondroitin 
sulphate proteoglycan (MCSP), a proteoglycan that is expressed on the surface of melanoma 
cells [77].  
 Ack1 is autophosphorylated in the activation loop at tyrosine 284 [78]. Other 
Ack1 phosphorylation sites identified by proteomic approaches include Y826, Y856, and Y857 
[74].  Phosphorylation of Y826 was identified downstream of insulin signaling and Y857 
downstream of Her2 [74]. Ack1 cancer associated mutation E346K was identified in ovarian 
endometrioid carcinoma and destabilizes an auto-inhibited conformation of Ack1, leading to 
constitutively high Ack1 activity [79]. Mutations V365R in the kinase region, F820A in the 
Mig6 homology region (MHR) also seem to destabilize the auto-inhibition and activate Ack1 
[79]. Other mutations that activate Ack1 include R34L found in lung adenocarcinoma and R99Q 
in ovarian carcinoma occurring in the SAM domain and M409I mutation in lung 
adenocarcinoma in the SH3 domain [74]. Generated mutations W426K, that prevents binding of 
the SH3 domain to its ligand, produced Ack1 activation while the H464D point mutation that 
disrupts Cdc42 binding reduced Ack1 autophosphorylation [71]. The down-regulation of Ack1 
involves an intramolecular interaction of the MHR with the kinase domain [79].  
 As mentioned previously, Ack1 gene amplification and mRNA overexpression 
play a role in carcinogenesis. Ack1 gene amplification was shown in 9% of lung tumors and 14% 
of the ovary tumors [70]. In addition, 42% of aggressive lung tumors and 77% of metastatic 
hormone refractory prostate tumors showed overexpression of the Ack1 mRNA [70]. Ack1 
overexpression increased migration of human mammary epithelial cells (HMECs) and increased 
metastasis in the mouse mammary 4T1 breast cancer system [70]. Ack1 expression also plays a 
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role in epithelial-to-mesenchymal transition (EMT). Ack1 has been shown to play a role in 
promoting prostate tumorigenesis by Wwox tumor suppressor degradation, phosphorylation and 
activation of AR, and phosphorylation of Akt [80-82]. Ack1 phosphorylates the pro-apoptotic 
WW domain containing oxidoreductase (Wwox) at tyrosine 287 which leads to the dissociation 
of Ack1-Wwox complex and Wwox polyubiquitination and degradation [82]. Constitutive active 
Ack1 with a L487F mutation, which disrupts auto-inhibition of Ack1, was shown to promote 
prostate xenograft tumor growth in mice (Fig 1.5) [81, 82]. In addition to the inhibition of tumor 
suppressor Wwox by Ack1, Ack1 enhances AR transcriptional activity, increases AR 
recruitment, and promotes androgen independent tumor growth through AR tyrosine 
phosphorylation at Tyr-267 and Tyr-363 (Fig 1.6) [81]. Tumor samples showed increased Ack1 
and AR phosphorylation; particularly 44% of CRPC tumors had AR phosphorylation while none 
of 13 androgen-dependent prostate cancer (ADCaP) tumors or 18 BPH samples showed AR 
tyrosine phosphorylation [81]. Activation of Ack1 and subsequent phosphorylation of AR at Tyr-
267 was induced by EGF, heregulin, and Gas6 and inhibited by Src kinase inhibitor dasatinib 
[53]. Hence, Ack1 role in tumorigenesis and particularly in the prostate is an important 
mechanism of cancer progression and maintenance. 
1.7 Co-repressors NCoR1/SMRT 
Nuclear receptor co-repressor (NCoR1) is a ~270kDa protein isolated using a 
thyroid/retinoid-X receptor bait [83]. Silencing mediator for retinoic acid and thyroid hormone 
receptor (SMRT) is a paralog of NCoR1 with ~48% homology [84]. NCoR1 contains three C-
terminal receptor interaction domains (RID) while SMRT contains two. The RID domains 
contain a hydrophobic (I/LXXII) core termed CoRNR box which is involved in nuclear receptor 
interaction [85]. NCoR1 and SMRT also contain a Sin3 interacting domain (SID) domain and 
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three N-terminal repressor domains (RD) which recruit additional components (Fig 1.7). The 
repressive ability of NCoR1/SMRT is attributed to the N-terminal RD domains which also 
contain motifs SANT1 and SANT2 (Swi3/Ada2/N-Cor/TFIIID) between RD1 and RD2. The 
SANT1 submotif plays a critical role in the interaction with HDAC3 through the deacetylase 
interaction domain (DAD) [86]. The SANT2 motif enhances the repression of SANT1/HDAC3 
by acting as a histone interaction domain (HID) [87]. RD1 of NCoR1 binds HDAC1 and 2 via 
Sin3 co-repressor while RD3 binds HDAC 4, 5, and 7 [88-90].  
NCoR1 knockout mice are lethal at embryonic development day E15.5 [91]. Phenotypes 
involve smaller livers, small body size, erythropoietic defects, and abnormal nervous system 
development [91]. SMRT behaves similarly to NCoR1 in terms of HDAC association with its 
domains. SMRT/HDAC3 activation requires chaperone TRiC-1 dissociation in an ATP 
dependent manner upon complex formation [92]. SMRT knockout mice are embryonically lethal 
by E16.5 due to cardiogenic defects [93, 94]. Rescue of the cardiac defects of SMRT null mice 
were obtained with re-expression of alpha-myosin heavy chain SMRT [93]. Though the mice 
survived till birth, they exhibited major defects in neural development [93]. 
 NCoR1 interacts directly with AR to repress DHT stimulated transcriptional 
activity [95]. The C-terminal region of NCoR1 was necessary for repression as mutations in the 
CoRNR box ablated repression [95]. NCoR1 can also inhibit co-activator binding to AR like 
SRC-1 by interacting with the AR N-terminal region [96]. NCoR1-AR interaction was also 
shown to be enhanced when cells were treated with steroidal antagonist mifepristone (RU486) 
which prevents the formation of the co-activator binding site [96]. NCoR1 expression has a cell 
cycle regulation where it is increased in S-phase and G2/M phase while minimal in G1[97]. 
Some evidence indicates that NCoR1 can regulate AR target genes where NCoR1 chromatin 
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binding to ARE regions was only seen in S-phase [97]. Furthermore, it was shown that NCoR1 
and AR interacted with each other in the DNA binding regions of AR target genes [97]. SMRT is 
involved in the ability of anti-androgen cyproterone acetate (CPA) to inhibit AR transactivation 
but not other anti-androgens [98]. SMRT behaves similarly to NCoR1 in that it interacts directly 
with AR through the RD2 domain, inhibits DHT-bound AR, and competes with p160/TIF2 co-
activator for binding [99]. Additionally, analysis of over 200 prostate cancer tumors showed that 
4% of primary tumors and 16% of metastatic tumors had loss of NCoR1 and 23% of primary and 
21% of metastatic tumors had a loss of SMRT [50]. 
1.8 Co-repressor SHARP 
A yeast-2-hybrid screen utilizing the SMRT LBD domain as bait identified 
SHARP/SPEN (SMART/HDAC1-associated repressor protein) [100]. SHARP is a 3651 amino 
acid polypeptide that is a ~400 kDa protein. SHARP contains SID/RD (SMRT interaction 
domain/repression domain) at the C-terminus, three RRMs (RNA recognition motifs at the N-
terminus, four NLSs (nuclear localization signal), and a RID (receptor interaction domain) (Fig 
1.7) [100]. SHARP is expressed at high levels in brain, testis, spleen, and thymus and at lower 
levels in kidney, liver, mammary gland, and skin [100]. SHARP acts as a co-repressor of nuclear 
receptor signaling where it can recruit and interact with HDAC1 [100]. GST-pull down with RT-
PCR revealed that SHARP interacts directly with RNA co-regulator SRA, repressing SRA 
mediated ER transcriptional activity [100]. Furthermore, SHARP interacts with transcriptional 
repressor RBP-Jk/CBF-1 to repress transcription in an HDAC-dependent manner in the absence 
of activated Notch signaling [101]. It was demonstrated that the Hes1 promoter, a Notch target 
gene, was repressed by SHARP in a RBP-Jk dependent manner [101]. Notch signaling activation 
by ligand Delta can suppress neuronal differentiation [102]. SHARP was shown to interfere in 
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Notch signaling in neurogenesis of Xenopus where constitutively active Notch resulted in no 
lateral and no intermediate primary neurons [101]. However, when SHARP RNA was co-
injected, it rescued the formation of intermediate and lateral primary neurons indicating its 
importance in neurogenesis [101].  
1.9 Co-regulator SRA and Co-repressor SLIRP 
Steroid receptor RNA activator, SRA, was the first to be identified as a co-regulator that 
acts as an RNA transcript and exists in a ribonucleoprotein complex with co-activator SRC-1 
[103]. Using a yeast-2-hybrid assay with AF1-containing N-terminus of hPR, SRA was 
identified via screening of human cDNA libraries from skeletal muscle, heart, and the HeLa S3 
cell line [103]. SRA enhanced PR transactivation when induced with progestin [103]. Further 
analysis of other steroid receptors revealed that SRA enhanced steroid receptor mediated 
transactivation of GR, AR, ER, thyroid hormone (TR), retinoic acid (RAR and RXR), and 
peroxisome proliferator activated receptor (PPAR) [103]. Secondary structure predictions 
suggest that there are multiple stem-loop structures where co-activators and co-repressors bind 
[100, 104, 105]. SRA has been shown to associate with co-regulators SRC-1, PGC-1, SHARP, 
and SLIRP. 
SLIRP (SRA stem-loop interacting RNA binding protein) was identified as a SRA 
binding protein at stem loop seven. [105]. SLIRP is mainly composed of a RNA recognition 
domain (RRM) with 2 submotifs, RNP1 and RNP2 (Fig 1.7) [105]. SLIRP is a 109 amino acid 
protein that also contains a putative mitochondrial localizing signal (MLS) at the N-terminus 
[105]. SLIRP RRM homology is very similar to another co-repressor, SHARP, inferring that 
SLIRP and SHARP may bind similar partners [105]. For example, both SLIRP and SHARP can 
bind STR7 of SRA [105]. SLIRP is located on Chr 14q24.3 next to co-activator SKIP implicated 
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in oncogenesis [105]. SLIRP mRNA is ubiquitously expressed with the highest levels in heart, 
liver, skeletal muscle, and testis [105]. SLIRP was detected in breast cancer cell lines SK-BR-3, 
MCF-7, and MDA-MB-468 and prostate cancer cell line LNCaP [105].   
SLIRP can repress SRA mediated transaction of Estrogen receptor (ER) luciferase 
reporter [105]. Furthermore, SLIRP can modulate other nuclear receptors including 
glucocorticoid (GR), androgen (AR), thyroid (TR), and Vitamin D receptor (VDR) [105]. When 
SLIRP is co-transfected with SHARP and SRA, repression of ER signaling is further enhanced 
[105]. SLIRP competes with other co-activators like SKIP for SRA binding to regulate NR 
signaling. Imaging studies show that SLIRP mainly colocalizes to the mitochondria and only a 
small percentage is localized in the nucleus [105]. SLIRP knockout mice are viable but sub-
fertile [106]. The percentage (21%) of SLIRP knockout mice born were less than what was 
predicted with Mendelian genetics [106]. SLIRP KO mice produced less progressively motile 
sperm, has interruption of the mid-piece/annulus junction, and altered mitochondrial morphology 
compared to the WT mice [106].  
In the mitochondria, SLIRP maintains mitochondrial-localized mRNA transcripts that 
encode Oxidative Phosphorylation (OxPhos) protein subunits [107]. The OxPhos pathway is 
important in energy homeostasis by serving as the cell's producer of ATP [107]. OxPhos consists 
of five complexes and Complexes I through IV comprise the oxygen-dependent electron 
transport chain in charge of driving the generation of ATP by complex V. There are thirteen 
subunits that are encoded by mitochondrial DNA (mtDNA) and the remaining subunits are 
encoded by nuclear genes that are imported into the mitochondria. Baughman et al applied an 
expression screening to the OxPhos pathway using the 1427 microarray dataset compendium and 
identified SLIRP as a candidate protein involved in OxPhos [107]. SLIRP knockdown reduced 
  
  19 
abundance of complex IV subunit and COX2 and thus shows that SLIRP is important in OxPhos 
function by regulating mtRNA abundance [107]. Furthermore, SLIRP was found to co-
immunoprecipitate with LRPPRC [108]. Mutations in LRPPRC, a leucine-rich protein of the 
pentatricopeptide repeat family, leads to French Canadian variant of Leigh syndrome (LSFC), an 
early onset and fatal, neurodegenerative disorder. LRPPRC plays a role in regulating the stability 
and handling of mature mRNAs like cytochrome C oxidase (COX) subunits [108]. Accordingly, 
LRPPRC/SLIRP complex can also suppresses mRNA degradation mediated by PNPase and 
SUV3 and promote polyadenylation of mRNA mediated by mitochondrial poly (A) polymerase 
MTPAP [109]. Hence, in the mitochondria, SLIRP can form a complex with LRPPRC and 
together they regulate the stability of mtRNAs that are required for proper energy homeostasis. 
1.10 Dissertation Research Objectives: 
Castration resistant progression of prostate cancer (CRPC) is terminal and no curative 
treatment options exist for patients. A hallmark of CRPC is the reactivation of androgen receptor 
(AR) and thus identifying how AR is reactivated in the last stage of metastatic prostate cancer is 
crucial to treating patients. We previously demonstrated that Ack1 (activated cdc42-associated 
kinase) promotes growth of prostate xenograft tumors in castrated animals by activation of AR 
through phosphorylation of the Tyr-267 site [81]. However, the molecular mechanisms 
underlying activation of AR by Ack1 need to be fully elucidated. Thus, we wanted to identify 
any candidate proteins that may differentially interact with AR. We utilized the proteomics-
based approach of Differential In-Gel Electrophoresis (DIGE) and searched for proteins whose 
interaction with AR was regulated by Ack1 and that co-immunoprecipitated with AR. Using this 
approach, we identified the candidate protein SLIRP that was shown to be involved in estrogen 
receptor signaling [105]. Our objective is to: (1) Investigate candidate protein SLIRP as a co-
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repressor of AR signaling and if Ack1 is involved in SLIRP-AR interaction; (2) Characterize the 
loss of SLIRP in cell cycle regulation. Thus, understanding the mechanism of AR reactivation 
and its maintenance in CRPC is crucial in identifying novel targets and thus improving 
treatments for this patent population.
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Fig 1.1: Outline of Prostate Cancer progression.  
Patients diagnosed with localized prostate cancer undergo prostatectomy; however some patients 
develop metastatic disease. Common therapy for metastatic disease is androgen deprivation 
therapy. Unfortunately, 18-24months later, all patients develop castration resistant prostate 
cancer which is terminal. (Adapted from Scher, 2008 [110]) 
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Fig 1.2: AR antagonists utilized in CRPC Therapy.  
Different therapeutics target multiple parts of the androgen receptor signaling cascade. 
Abiraterone is a CYP17A1 inhibitor employed in CRPC that blocks intra-tumor conversion of 
progesterone and adrenal androgens to DHT. Enzalutamide (MDV3100), an AR inhibitor, 
prevents AR activation and translocation into nucleus. (Taken from Chen 2008, [111]) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  23 
 
 
 
 
 
Figure 1.3:  Full length and truncated AR modular structure and Co-activator interacting 
motifs.  
Top: AF1 is the ligand independent activating function domain located in the NTD while AF-2 is 
the ligand dependent domain in the C-terminus. AF-1 interacts with two motifs (FXXLF and 
WXXLF) in the NTD. LKDIL is a core motif that mediates transcriptional activity of TAU1 and 
co-regulators such as SRC/p160 which interacts with AF-2 through the LXXLF motifs (Adapted 
from Wilson, 2007[112]). Bottom: AR consists of N-terminal region (NTD), a DNA binding 
domain (DBD), Hinge region (H), a ligand binding domain (LBD). Truncated AR lacks the LBD 
and forms a ~80kDa protein. (Adapted from Lonergan 2011, Lallous 2013 [51, 113]) 
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Fig 1.4: AR in Cell Cycle 
Activated AR can stimulate Cyclin D1 accumulation by mTOR, expression of p21/Cip1, and 
degradation of p27/Kip1 to enhance CyclinD1/CDK4/6 and Cyclin E/CDK2 dependent 
inactivation of Rb. E2F is released and allows expression of E2F target genes like Cyclin A2 to 
help drive G1 to S transition. Elevated Cyclin D1 levels act as a negative feedback loop to 
attenuate AR activity. (Taken from Balk and Knudsen 2008, [57]) 
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Fig 1.5: Ack1 modular protein structure with mutations K158R and L487F. 
Ack1 is a non-receptor tyrosine kinase that contains a SAM (sterile-alpha motif) domain that 
promotes Ack1 dimerization at the plasma membrane to allow intermolecular auto-
phosphorylation. It also contains a NH2-terminal kinase domain, a Src homology domain (SH3), 
CRIB interacting domain, and a proline rich domain. The constitutively active (caAck1) 
mutation disrupts auto-inhibitory intramolecular interaction while the kinase dead (kdAck1) 
mutation is in the ATP acceptor site. (Adapted from Mahajan 2005, [82]).  
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Fig 1.6: Ack1 activation of the AR pathway 
Cell surface receptors are activated (by autocrine, paracrine, or mutational events) which leads to 
Ack1 kinase activation via auto-phosphorylation  Ack1 binds and phosphorylates AR 
proteinAR-Ack1 complex translocates to the nucleus bind to AREs on DNA as a 
dimeractivation of AR dependent gene expression. (Adapted from Mahajan 2007, [81]).  
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Fig 1.7: SLIRP, SHARP, NCoR1, and SMRT co-repressor protein modular structure. 
SLIRP has one main RRM with submotifs RNP1 and RNP2 for SRA recognition and an N-
terminal putative mitochondrial localizing signal. SHARP has multiple RRM domains which 
functions as a RNA recognition motif for binding RNA like SRA. SHARP can also recruit 
HDACs. NCoR1and SMRT contains C-terminal receptor interaction domains (RID) and three N-
terminal repressor domains (RD). Submotifs SANT1 and SANT2 (Swi3/Ada2/N-Cor/TFIIID) 
contain deacetylase interaction domain (DAD) and histone interaction domain (HID) 
respectively for HDAC recruitment. (Adapted from Hatchell 2006, Shi 2001, Huang 2000 [89, 
100, 105])   
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CHAPTER II: ACK1 MEDIATED REGULATION OF CO-REPRESSOR 
SLIRP IN AR SIGNALING 
 
2.1 Overview 
 
Prostate cancer progression into CRPC is dependent on androgen receptor (AR) 
reactivation. Multiple mechanisms enhance or activate AR including amplifications that 
sensitizes AR to low levels of androgens or mutations that confer responsiveness to other 
steroids besides the canonical ligands and phosphorylation of AR by kinases. In particular, we 
are interested in the activation of AR by the tyrosine kinase Ack1. We have previously shown 
that Ack1 phosphorylates AR and leads to a ligand independent activation. In order to 
characterize this mechanism further, we utilized DIGE proteomics to identify components 
important in this pathway. SLIRP was identified as a candidate protein and further investigation 
into this protein revealed that SLIRP works as a co-repressor in AR signaling. Treatment of 293T 
cells transfected with AR and constitutively active Ack1 (caAck1) or LNCaP cells treated with 
DHT or caAck1 revealed that SLIRP associates with AR in the absence of AR activation. 
However, in the presence of DHT stimulation or Ack1 phosphorylation of AR, SLIRP 
dissociates from this complex and AR dependent gene transcription is initiated. Furthermore, in 
the presence of SLIRP, AR transactivation is repressed as measured by luciferase reporter 
activity and AR transactivation is increased with the knockdown of SLIRP. Using quantitative 
PCR we show that knockdown of SLIRP enhances endogenous transcription of AR dependent 
genes PSA and hK2. The ChIP assay showed that SLIRP is recruited to AR gene enhancers 
including PSA and hK2 in the absence of AR activation by DHT or heregulin and in the presence 
of AR antagonist bicalutamide. However, in the presence of these factors, SLIRP recruitment is 
reduced. These data suggest that SLIRP associates with AR in a co-repressor complex and when 
AR is activated, SLIRP dissociates from the complex and gene transcription is activated. 
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2.2 Introduction  
Androgen receptor (AR) is a steroid receptor involved in prostate development and 
prostate cancer. Androgen deprivation therapy is used to treat patients but the cancer ultimately 
develops into castration resistant prostate cancer (CRPC). There is substantial evidence 
indicating AR activation in low androgen environments through AR gene amplification, 
increased AR expression, AR point mutations occurring in the ligand binding domain that 
broaden ligand specificity, AR splice variants, and over-expression of AR co-activators [26-29]. 
When AR was over-expressed in androgen dependent xenografts, it enhanced the ability to form 
tumors in castrated mice while AR knockdown inhibited their tumorigenicity [114]. Prostate 
xenograft studies illustrate that tumors that recur after castration express AR dependent genes 
[115]. Furthermore, AR protein is stabilized and constitutively localized to the nucleus and 
becomes hypersensitive to low levels of androgen [116]. AR protein phosphorylation by non-
receptor tyrosine kinases Src and Ack1 in an androgen independent manner have been indicated 
to play a role in the development of CRPC [81, 117, 118]. Src kinase phosphorylates AR at Tyr-
534, leading to nuclear translocation and activation of AR dependent gene regulation [117, 118]. 
Ack1 (activated cdc42-associated kinase) expression is shown to be higher in CRPC tissue than 
primary prostate cancer tissue samples [70]. Specifically, Ack1 promotes prostate tumorigenesis 
by Wwox tumor suppressor degradation and phosphorylation of AR at Tyr-267 and Tyr-363 
leading to activation of AR [81, 82]. Constitutively active Ack1 with a mutation that disrupts 
autoinhibition of Ack1 enhances AR transcriptional activity, increase AR recruitment, and 
promote androgen independent xenograft tumor growth [81]. 
 In addition to the mechanisms that activate AR, there are multiple co-repressors 
that regulate AR activity through its inhibition. NCoR1 and SMRT can interact directly with AR 
  
  30 
through the RD2 domain and inhibit DHT-bound AR. NCoR1 and SMRT have also been shown 
to recruit HDACs to aid in receptor repression [83, 84, 86]. Another nuclear steroid receptor co-
repressor, SLIRP (SRA stem-loop interacting RNA binding protein), represses receptors 
including PPAR, VDR, and TR [105]. The majority of SLIRP is co-localized to the mitochondria 
with a small percentage in the nucleus [105]. SLIRP in the mitochondria maintains 
mitochondrial-localized mRNA transcripts that encode Oxidative Phosphorylation (OxPhos) 
subunits [107]. SLIRP has also been shown to interact with LRPPRC in a ribonucleoprotein 
complex that may regulate the stability of mature mRNAs [108].  
RNA co-regulator SRA recruits SLIRP to estrogen receptor (ER) via binding to stem 
loop 7 and has been shown to repress SRA mediated ER transactivation [105]. SLIRP’s role with 
other steroid receptors led us to the hypothesis that SLIRP may act as a co-repressor of AR 
signaling. Our studies found that SLIRP over-expression reduced AR transactivation where 
knockdown increased it in a dose dependent manner. Furthermore, SLIRP knockdown enhanced 
endogenous transcription of AR dependent genes PSA and hK2. Even more interestingly, we 
find that SLIRP associates with AR but this association is disturbed by AR activation by DHT or 
Ack1. Moreover, DHT or heregulin treatment leading to Ack1 activation reduces recruitment of 
SLIRP to AR gene enhancers. SRA knockdown also reduces SLIRP association with AR. The 
model formed from this data dictates that SLIRP exists in a co-repressor complex with AR in the 
absence of ligand or kinase activation. However, when AR is activated by ligand binding or 
Ack1 phosphorylation of this complex, SLIRP dissociates from the complex and presumably co-
activators are recruited to induce AR dependent transcription.  
 
 
  
  31 
2.3 Materials and Methods 
Cells and reagents- LNCaP cells and 293T cells were obtained from the American Type 
Culture Collection (Manassas, VA, USA). Short tandem repeat (STR) authentication of LNCaP 
cell line was conducted (UNC Tissue Culture facility). DHT (Sigma-Aldrich, St Louis, MO, 
USA), EGF (R&D Systems, Minneapolis, MN, USA), IL-6 (R&D Systems), gas6 (R&D 
Systems) and bombesin (Sigma-Aldrich, St Louis, MO, USA) were purchased. Heregulin was a 
gift from Genentech (South San Francisco, CA, USA). Dasatinib was obtained from Bristol-
Myers-Squibb (Princeton, NJ, USA). U0126 MEK inhibitor and luciferase assay kit were 
acquired from (Promega, Madison, WI). A mouse monoclonal antibody against AR (F39.4.1, 
Biogenex, San Ramon, CA, USA) was used for immunoblotting and a polyclonal antibody 
against AR (C-19, Santa Cruz) was used for immunoprecipitation. The antibody against total 
Ack1 was described previously (Mahajan et al 2005). A phospho-specific antibody against Ack1 
p-Tyr-284 (# 09–142) was obtained from Millipore (Billerica, MA, USA). Antibody against 
SLIRP (#ab51523) was purchased from Abcam (Cambridge, MA, USA). Actin antibody and 
agarose A protein beads were purchased from Santa Cruz biotechnology (Santa Cruz, CA, USA). 
Anti-FLAG affinity gel (#A2220) and EZ view Red anti-FLAG beads were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Custom nonsense control (NS) siRNA 
(GUUCAGGUCGAUAUGUGCA) and SMARTpool SRA siRNA (L-027192-00) was obtained 
from Dharmacon (Thermo Scientific Dharmacon, Pittsburgh, PA). A pool mix of SLIRP siRNA 
from Invitrogen (HSS130109, HSS188666, HSS188667; Life Technologies, Grand Island, NY) 
was used. GAPDH (Left 5’ACAGTCAGCCGCATCTTCTT3’, Right 
5’GACAAGCTTCCCGTTCTCAG3’) and SRA (Left 5’ATGGAGGATGTGCTGAGACC3’, 
  
  32 
Right 5’GCTGCCTCCTCTGAAAACAG3’) primers were used for PCR (UNC Nucleic Acid 
Core Facility, Chapel Hill, NC) 
Plasmids-The plasmids encoding AR, truncated AR (Tr-AR), wild-type (wt) Ack1, 
kinase dead (kd) Ack1, constitutively active (ca) Ack1, and the ARR2-PB-luciferase reporter 
were described previously (Mahajan NP, 2007) (Mahajan NP, 2005). FLAG-SLIRP and SRA 
expression vectors were purchased from Origene Inc. (Rockville, MD, USA). Y267F, Y363F, 
Y534F mutants of AR were obtained using Stratagene QuikChange™ Site-Directed Mutagenesis 
kit (La Jolla, CA, USA). The sequence was confirmed by direct sequencing.  
Differential in gel electrophoresis – mass spectrum (DIGE-MS) assay- HEK 293T cells in 
10cm culture dish were transfected with the expression vectors encoding AR (1µg), or AR (1µg) 
plus constitutively active Ack1(1µg) using effectene. After 24 hrs, protein extracts were 
harvested and immunoprecipitated with 6ul (2ug) AR antibody plus 30ul agarose A beads 
overnight. The precipitant was analyzed using one-dimensional DIGE method in UNC Systems-
Proteomics Core Facility, following protocols described previously (Alzate O., et al, 2004). The 
spot of interest was picked and analyzed by mass spectrometry at UNC Proteomics Core Facility. 
The resulting peptides were mixed with matrix (α-Cyano-4-Hydroxycinnamic Acid) and 
analyzed using a MALDI-TOF/TOF mass spectrometer (Applied Biosystems 4800 Plus). MS 
spectra were obtained in reflector positive ion mode and peaks with signal-to-noise ratio above 
20 were selected for MS/ MS analysis (maximum of 45 MS/MS spectra per spot). All spectra 
were searched using GPS Explorer Software Version 3.6 (Applied Biosystems) linked to the 
Mascot (Matrix Science, Inc.) search engine 
Western -HEK 293T cells were co-transfected with wt-Fl-AR, wt-Tr-AR, Y267F, 
Y363F, or Y534F AR mutants and PCDNA3 vector, wt, ca, or kd Ack1 constructs while LNCaP 
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cells were transfected with the Ack1 constructs. After 24hrs of transfection, cells were treated 
with vehicle control, DHT (10nM), heregulin (10ng/ml), EGF (100ng/mL), IL-6, or bombesin 
for another 24hrs. Protein extracts were quantified by Bradford assay (Bio-Rad Laboratories, 
Hercules, CA) and analyzed by SDS-PAGE as previously described (Steinbrecher et al., 2005). 
Samples were immunoprecipitated using AR antibody (C-19, Santa Cruz) plus protein A agarose 
beads or FLAG beads overnight. For knockdown experiments, SRA-siRNA (25nM, 50nM, 
100nM) and non-sense (NS) control was transfected and RT-PCR was done to analyze SRA 
knockdown. Cells were transfected with control siRNA or SRA-siRNA (50nM) and transfected 
with Ack1 or treated with DHT. Immunoprecipitation was carried out using AR antibody and 
immunoblotted as indicated previously. 
Immunoprecipitation RT-PCR Assay- This assay was done following the protocol 
described elsewhere (Giles et al., 2003). Briefly, cell lysate from SRA-siRNA treated LNCaP 
cells was immunoprecipitated with SLIRP IgG, AR IgG, non-specific Rabbit IgG, or no IgG. 
Total RNA was isolated from immunoprecipitated fraction using tri-reagent (Molecular Research 
Center, Inc. Cincinnati, OH, USA). SRA RT-PCR was conducted following the protocol 
described above. 
Luciferase assay- LNCaP cells were plated at 6X10^4 cells/ well in a 12-well plate in 
replicates of 4. Cells were co-transfected with ARR-2PB-Luciferase or MMTV-luciferase 
(Zhang et al., 2000) and vector or SLIRP-FLAG-WT for 24hrs using effectene (Qiagen, 
Valencia, CA) kit in charcoal strip (-Phenol red) RPMI-1640 media. For knockdown studies 
nonsense siRNA or SLIRP-siRNA pool were used. After 24hrs of transfection, cells were 
washed with 1xPBS and treated with vehicle EtOH or 1nM DHT treatment in SFM for another 
24hrs. Cells were harvested using lysis buffer provided in Promega luciferase kit and assayed 
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according to manufacture’s protocol. Statistical analysis was done with Graphpad prism (La 
Jolla, CA) using unpaired T-test. 
Real-time Quantitative PCR- LNCaP cells were transfected with NS control siRNA or 
pool mix of SLIRP siRNA at 40nM for 24hrs. Cells were washed once with 1x PBS and replaced 
with serum free media containing EtOH or 1nM/ml DHT for another 24hrs. RNA was collected 
using Qiagen RNeasy kit (74104) and cDNA was generated using Biorad iscript cDNA synthesis 
kit (Bio-Rad Laboratories, Hercules, CA). Real-time PCR was conducted using GAPDH (probe-
FAM-CAGCCTCAAGATCATCAGCAATGCCTC-BHQ, Fp-
GTCATGGGTGTGAACCATGAGA, Rp-GGTCATGAGTCCTTCCACGATAC), PSA (probe-
FAM-ATGACGTGTGTGCGCAAGTTCACCC-BHQ, Fp-GTTTTTGCCTGGCCCGTAG, Rp-
GCATGAACTTGGTCACCTTCTG), hK2 (probe-TGACCTCATGCTGCTCCGCCTGT, Fp-
GCCTTAGACCAGATGAAGACTCCA, Rp-GCCCAGGACCTTCACAACATC), and SLIRP 
(probe-CGGCCATGTCAGAAGGTGCA, Fp-GCGCTGCGTAGAAGTATCAA, Rp-
ACTGAACCCAACCCAAACCT) sets.  
Chromatin Immunoprecipitation (ChIP) assay- Cells were lysed in lysis buffer 
containing 50mmol/L Tris-HCl, 0.1% NP40, 150mmol/L NaCl, 10% glycerol, 2mmol/L EDTA, 
plus proteinase inhibitor (Roche Diagnostic, Indianapolis, IN, USA) and phosphatase inhibitor 
(St. Louis, MO, USA). Immunoprecipitation was done by incubating the mixture of 500 µg 
protein lysis with 2 µg IgG and 50 µL protein A agarose beads overnight at 4°C. 
Immunoprecipitated fraction was resolved on 4-12% Bis-tris gel (Invitrogen, Carlsbad, CA, 
USA). For immunoblotting, antibodies were prepared at 1:1000 dilution unless specifically 
indicated. ChIP analysis was performed following the protocol described before (Liu YB, 2005) 
(Mahajan et al., 2007). Briefly, an antibody against AR (Santa Cruz Technology, Santa Cruz, 
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CA) or SLIRP (Abcam, Cambridge, MA, USA) was applied to immunoprecipitate DNA which 
was associated with AR and SLIRP. DNA was subjected to quantitative PCR using the primers 
and the probe targeting the distal ARE III enhancer sequence of the PSA gene or the primers and 
the probe targeting the distal enhancer of the hK2 gene as described previously.  
2.4 Results  
AR interaction with SLIRP is disrupted by Ack1 activation 
To investigate potential interactors of AR affected by Ack1, we employed the 
Differential in Gel Electrophoresis (DIGE) proteomics technique to identify proteins whose 
expression changed in the absence and presence of Ack1. As shown in Fig 2.1A, one band 
demonstrated reduced binding to AR in Ack1 transfected cells compared to AR only cells. We 
isolated the band and analyzed it by mass spectrometry and identified SLIRP as a possible 
candidate interactor. In order to confirm our proteomics data, we immunoprecipitated AR and 
looked at SLIRP protein co-immunoprecipitation in the presence of wild-type Ack1, 
constitutively active Ack1 (caAck1), and kinase dead (kdAck1) in 293T cells (Fig 2.1B). SLIRP 
co-immunoprecipitation with AR was demonstrated in the absence of Ack1 or in the kinase dead 
form. However, in the presence of Ack1 expression, SLIRP co-immunoprecipitation is reduced 
or lost.  Furthermore, DHT treatment was also shown to disrupt interaction between SLIRP and 
AR (Fig 2.1C). This was confirmed with endogenous SLIRP and AR in the prostate cancer cell 
line LNCaP (Fig 2.1D). Immunoprecipitation of SLIRP demonstrated reduction of AR 
association with SLIRP in the presence of DHT stimulation or Ack1 activation (Fig 2.1E). Thus, 
we show that SLIRP association with AR is disrupted by ligand DHT or kinase Ack1 activation 
of AR. 
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Disruption of SLIRP-AR interaction is independent of known Ack1 phosphorylation 
It has been shown that growth factors heregulin and gas6 can induce Ack1 
phosphorylation of AR at Tyr-267 while Tyr-534 phosphorylation by Src kinase is induced by 
EGF, bombesin or- IL-6 stimulation [53]. SLIRP association was almost completely lost in the 
presence of heregulin treatment and thus Ack1 activation but not in the presence of other growth 
factors in LNCaP cells (Fig 2.2A). There is a small change in SLIRP complex with AR with both 
IL-6 and bombesin stimulation. Since neither of these ligands induce Ack1 mediated activation 
of AR, there is the possibility of another kinase leading to SLIRP dissociation. We have 
previously shown that dasatinib, a Src inhibitor can inhibit heregulin induced Ack1 
phosphorylation of AR [53].  SLIRP association with AR which is disrupted by heregulin 
treatment is reestablished by dasatinib inhibition of Ack1 activity (Fig 2.2B). In contrast, the 
MEK inhibitor U0126 could not reverse the disruption of the SLIRP-AR association after 
heregulin treatment, showing that the ERK pathway does not play a role in this interaction. We 
next determined if the kinase activity of Ack1 was important for the dissociation of SLIRP from 
AR. We previously demonstrated that Ack1 phosphorylates AR at Tyr-267 and to a lesser extent 
Tyr-363 [81]. However, SLIRP does not contain any tyrosine residues. Hence, we used AR 
mutants where the tyrosine is changed to a phenylalanine to determine if these Ack1 target 
phosphorylation sites of AR were important in the dissociation of SLIRP from AR. Surprisingly, 
none of these AR tyrosine point mutants reestablished SLIRP interaction with AR (Fig 2.2C). 
We also determined whether SLIRP interacted with N- or C-terminal of AR. We found that C-
terminal truncated AR (aa1-660) lacking the ligand binding domain (LBD) did not associate with 
SLIRP (Fig 2.2D). Thus, we identified a dynamic relationship between SLIRP, AR, and Ack1 
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where the complex between SLIRP and AR is disrupted by AR activation by either its ligand 
DHT or the tyrosine kinase Ack1.  
SRA is necessary in SLIRP-AR interaction 
It has been illustrated that RNA co-regulator SRA is important in SLIRP interaction with 
ER. Specifically, SLIRP is recruited to ER via binding of stem-loop 7 on SRA to mediate ER 
repression [105]. Therefore, we wanted to investigate the role of SRA in SLIRP-AR interaction. 
First, we established that SRA siRNA reduced RNA levels of SRA (Fig 2.3A). We found that 
DHT minimally induced SRA RNA levels while Ack1 had no affect (Fig 2.3B). SRA 
knockdown abrogated the interaction between AR and SLIRP in LNCaP cells, demonstrating 
that SLIRP interaction with SRA is necessary in AR binding (Fig 2.3C and D). Therefore, SRA 
could also recruit SLIRP to AR in the same manner as SLIRP is recruited to ER, by binding to 
STL7. Moreover, Ack1 or DHT treatment did not affect SRA-SLIRP or SRA-AR interaction 
(Fig 2.3 E and F). We do note a small increase of SRA RNA levels (Fig 2.3B) and increase in 
SRA association with AR with DHT stimulation that is not seen with Ack1 (Fig, 2.3E and F). 
Since SRA can act as a co-activator that can recruit SRC-1, a known AR coactivator, DHT 
stimulation could enhance the interaction of SRA with AR to enhance co-activator recruitment 
[103]. However, Ack1 may work through a different mechanism where SRA levels are not 
affected as inferred by the qRT-PCR and IP-RT-PCR (Fig. 2.3B and E) as there are multiple 
ways to control AR activity. Hence, due to the fact that SRA can act as either a co-activator or 
co-repressor depending on its interacting partners could account for the unchanged interaction 
between SRA and AR. 
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SLIRP is a co-repressor of AR signaling 
Now that we have established a relationship between AR and SLIRP, we wanted to 
investigate the functional significance of SLIRP expression in the AR pathway. We first 
established our SLIRP siRNAs knockdown SLIRP in LNCaP cells (Fig 2.4A). Since SLIRP is 
mainly a mitochondrial protein, we also confirmed knockdown of SLIRP in the nucleus using a 
pool of our SLIRP siRNAs (Fig. 2.4B). Using the androgen dependent probasin promoter PB 
linked to two androgen response regions (ARR2PB) luciferase reporter, we looked at SLIRP 
effect on AR transactivation. SLIRP overexpression results in reduction in AR transactivation in 
a dose dependent manner (Fig 2.5A). Conversely, SLIRP knockdown results in increased AR 
transactivation in a dose dependent manner (Fig 2.5 B). This implicates SLIRP as a negative 
regulator of AR transactivation. To further investigate SLIRP’s role as a repressor, we looked at 
two canonical AR dependent genes, PSA and hK2. SLIRP knockdown resulted in an increase in 
endogenous transcriptional activity of PSA and hK2 which was enhanced by DHT treatment (Fig 
2.5 C). The effect of SLIRP knockdown on hK2 transcription was more prominent than on PSA, 
suggesting that SLIRP repression of AR dependent genes may vary. Both DHT stimulation and 
Ack1 activation of AR leads to SLIRP dissociation from AR. Hence, we wanted to investigate 
whether recruitment of SLIRP to androgen response elements (ARE) in the absence or presence 
of either were affected. SLIRP was bounded to both the PSA and hK2 AREs in the absence of 
DHT and DHT treatment inhibited SLIRP recruitment to the AREs (Fig 2.6A and B). 
Additionally, AR antagonist bicalutamide (casodex) did not affect SLIRP recruitment to PSA 
and hK2 AREs while Ack1 activation via heregulin treatment inhibited SLIRP recruitment (Fig 
2.6 C and D). The data further substantiates the effect of Ack1 or DHT on SLIRP-AR 
dissociation. 
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2.5 Discussion 
We conclude with identifying a novel mechanism of AR repression that maybe perturbed 
in CRPC. We had identified a potential AR interactor, SLIRP, using proteomics and 
immunoprecipitation techniques. We have shown that both ligand activation and Ack1 kinase 
activation of AR disrupts the association of SLIRP with AR. AR activation by EGF and 
bombesin occurs through Src kinase phosphorylation of AR at Tyr-534 [117-119]. Heregulin 
activates Ack1 via HER-2 receptor to phosphorylate AR at Tyr-267 and Tyr-363. We found that 
heregulin treatment of LNCaP cells but not EGF treatment resulted in the loss of SLIRP. IL-6 
and bombesin affected SLIRP association with AR marginally. Neither bombesin nor IL-6 
treatment results in AR phosphorylation of Tyr-267 and Tyr-363 by Ack1 inferring that an 
alternate kinase may be activated by these ligands  [53]. A potential candidate that would be 
interesting to investigate is Src kinase as this kinase can lead to AR phosphorylation by both IL-6 
and bombesin stimulation. Furthermore, dasatinib, a drug that inhibits BCR/Abl and Src kinases 
and used in the treatment of chronic myelogenous leukemia (CML), was found to be an Ack1 
inhibitor in our work [53]. Thus, when we treated cells with dasatinib and heregulin, SLIRP was 
retained in the AR immunoprecipitation. Heregulin treatment can induce EGFR phosphorylation 
and hetrodimerzation with Her2 or Her 3 which can lead to AR phosphorylation [120]. Using 
MEK inhibitor, U0126, with heregulin demonstrated that Ack1 could still lead to SLIRP loss 
indicating that the EGFR pathway does not play a role.  
Moreover, the dissociation of SLIRP from AR is dependent on the kinase activity of 
Ack1. Though we have established that Ack1 can specifically phosphorylate AR at Tyr-267 and 
Tyr-363, we found that mutations of these sites still led to SLIRP dissociation from AR in the 
presence of Ack1.Thus, there are possible alternative Ack1 phosphorylation targets of AR. 
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Previous investigation into Ack1 mediated phosphorylation sites of AR using 
phosphoprotemomics and mass spectrometry has been challenging. Therefore, we could 
hypothesize that an unidentified AR tyrosine target site of Ack1 could be important in the 
mechanism of dissociation of SLIRP from AR.   
Furthermore, SLIRP dissociation from AR could be the result of Ack1 phosphorylation 
of another corepressor/component of the AR-SLIRP complex that has yet to be identified. 
NCoR1 and SMRT are well known co-repressors that can bind AR directly and inhibit AR 
signaling. However, NCoR1 and SMRT have weak interaction with unliganded AR but are 
recruited when AR is bound by antagonists such as cyproterone acetate, hydroxyflutamide or 
bicalutamide or agonists like DHT [95, 96, 99]. Other cofactors include those that recruit 
HDACs like androgen receptor corepressor-19 kDa (ARR19) which directly associates with AR 
and represses AR via recruitment of HDAC4 and FBI-1 which represses AR activity and can 
recruit HDACs [121, 122]. One candidate for the SLIRP co-repressor complex is SHARP, which 
like SLIRP can interact with RNA co-regulator SRA and repress steroid receptor signaling [100, 
105]. It was also shown that co-transfection of SLIRP and SHARP can enhance repression of ER 
signaling more than SLIRP alone [105].  
Both ligand and kinase activation of AR leads to reduced association of SLIRP with AR. 
This implies that there exist multiple mechanisms by which SLIRP association with AR could be 
lost. For instance, DHT binds the ligand binding domain (LBD) in the C-terminus which could 
disrupt SLIRP association with AR as SLIRP binding is lost with truncated AR that lacks the 
LBD. On the other hand, Ack1 could interact through the N-terminus, changing the conformation 
of AR to a more active state that results in the loss of SLIRP interaction. 
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 When we explored chromatin recruitment of SLIRP to multiple AR gene enhancers, we 
found that SLIRP recruitment is reduced by DHT or heregulin. However, SLIRP recruitment is 
restored with the addition of AR antagonist bicalutamide. It would be more informative to 
conduct ChIP-Seq experiments where we would be able to map all binding sites for SLIRP. Our 
model (Fig 2.7) illustrates a mechanism where SLIRP represses AR thereby controlling AR 
signaling but with the activation of AR by Ack1 or DHT, leads to the dissociation of SLIRP from 
AR, recruitment of co-activators possibly by SRA, and activation of AR dependent genes. 
Identification of interacting proteins in this complex would help in determining the 
mechanism of action of Ack1 in the interaction between SLIRP and AR. One approach to 
identifying interactors is to use a combination of cross-linking agents with immunoprecipitation 
followed by mass spectrometry analysis. Methods developed have incorporated antibody cross-
linking, Quantitative SILAC proteomics, and lysate cross-linking. For instance, Akt interactors 
were identified by using a two-step chemical cross-linking using DSS and DSP followed by Co-
IP and MS [123]. Furthermore, a study trying to profile post-translational modification (PTM) 
dependent protein-protein interaction like phosphorylation or methylation, combined photo-cross 
linking using benophenone with SILAC labeled cells to identify H3K4Me3 specific proteins 
[124]. Thus, focusing on identification and optimization of cross-linking agents like 
formaldehyde or NHS esters (amine) followed by in-gel or bead digestion and MS analysis could 
identify important SLIRP interactors that are apart of the AR-SLIRP co-repressor complex. 
Unraveling the complex is important in understanding how SLIRP works in the cell and 
eventually how SLIRP co-repressor function is lost in the progression of prostate cancer.  
 The current data illustrates that SLIRP expression reduces AR transactivation and 
the loss of SLIRP enhances transactivation. Moreover, knockdown of SLIRP results in the 
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enhancement of endogenous transcription of AR dependent genes PSA and hK2. For that reason 
SLIRP acts as a corepressor and negatively regulates AR transactivation. However, in the 
mitochondria, where SLIRP is mainly localized, it functions in mitochondrial RNA stability 
(mtRNA) of Oxidative phosphorylation (Oxphos) proteins and knockdown can reduce 
components of the Oxphos pathway [107, 108]. Oxidative phosphorylation is important as the 
main regulator of ATP. However, cancer cells rely more on glycolysis for energy production 
which is termed the “Warburg effect.”  We had analyzed the Oxphos pathway through oxygen 
consumption rate (OCR) and the glycolysis pathway by extracellular acidification rates (ECAR) 
measurements using XF24 Extracellular Flux Analyzer (Seahorse Bioscience, Massachusetts, 
US). We found that when SLIRP was knocked down by siRNA in LNCaP cells, there was 
increased glycolysis as measured by increases in ECAR compared to our control (data not 
shown). We would expect that SLIRP knockdown decreased OCAR or had no effect has high 
levels of SLIRP are associated with the mitochondria. Interestingly, we found that SLIRP 
knockdown enhanced OCAR levels and hence Oxphos (data not shown). Hence, there may be an 
alternative role of SLIRP in the mitochondrial besides maintaining mtRNA levels that would 
account for the OCAR increase.  
We also demonstrate the importance of RNA coregulator SRA in this complex. SRA was 
initially shown to act as a co-activator by interacting with SRC-1 coactivator and enhancing ER 
activation and later shown to recruit SLIRP or SHARP and repress ER activation [100, 103, 
105]. SLIRP interaction with AR was substantially lost with SRA knockdown showcasing the 
importance of SRA in the recruitment of SLIRP to AR. In addition, we found that SRA was not 
affected by Ack1 or DHT activation most likely due to the fact it can act as a co-activator as 
well. Thus, SRA could stay attached to AR functioning in the recruitment of co-activators.  
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Hence, SLIRP plays an important role in the regulation of AR in prostate cancer. CRPC 
tumors show Ack1 amplification and AR reactivation. The enhancement of Ack1 expression 
could lead to loss of SLIRP interaction with AR resulting in initiation of AR signaling. At least 
in part, SLIRP loss could lead to the abnormal reactivation of AR seen in CRPC. A study of 
tumor tissues ranging from BPH to metastatic CRPC investigating the expression of SLIRP 
could provide evidence of SLIRP as a potential biomarker of prostate cancer. Although there are 
some public databases that show SLIRP expression in some tumor cases and loss in others, there 
needs to be a detailed tumor study that specifically looks into the expression of SLIRP in tumors. 
It is important to understand the underlying relationship between Ack1, AR, and SLIRP because 
it would provide great insight to alternative mechanisms AR uses to escape regulation and thus 
properly design therapies to CRPC patients.  
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Figure 2.1: Ack1 and DHT impair the interaction between AR and SLIRP. (A) DIGE 
analysis in 293T cells. 293T cells were transfected with AR (1µg) only (Cy3) or AR (1µg) plus 
constitutively active Ack1 (1µg) (Cy5). Band indicated was isolated and analyzed through MS. 
(B) Ack1 activation (wild-type (wt) or constitutively active (ca)) interrupts the interaction of AR 
and SLIRP in 293T cells. The interruption is dependent on the kinase function of Ack1. (C) DHT 
treatment impairs the interaction between AR and SLIRP in 293T cells. (D) DHT and Ack1 
activation impairs the interaction between AR and SLIRP in LNCaP cells. (E) Association 
between AR and SLIRP is disrupted by DHT and Ack1 in 293T cells as demonstrated by SLIRP 
immunoprecipitation. These experiments were done by Dr. Zhentao (Richard) Zhang, in 
collaboration. 
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Figure 2.2: Effects of various growth factors, kinase ligands, AR mutants on AR-SLIRP 
interaction. (A) Effects of heregulin (10 ng/ml), EGF (100 ng/ml), gas6 (100 ng/ml), IL-6 (10 
ng/ml), and bombesin (1nM) on AR-SLIRP interaction in LNCaP cells. LNCaP cells were 
treated with the growth factors for 60mins in serum-free medium before harvest. (B) Dasatinib 
(10ng/ml) inhibits Ack1 kinase activity and maintains AR-SLRIP association with heregulin (10 
ng/ml) treatment in LNCaP cells. (C) AR tyrosine phosphorylation at Y267F, Y363F or Y534F 
does not contribute to the Ack1-induced AR-SLIRP dissociation in 293T cells. (D) Lack of the 
LBD (Tr-AR, aa 1-660) impairs AR-SLIRP interaction in LNCaP cells. These experiments were 
done by Dr. Zhentao (Richard) Zhang, in collaboration. 
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Figure 2.3: SRA is essential for AR-SLIRP interaction. (A) SRA knockdown by SRA-siRNA 
in 293T cells with non-sense (NS) control. Values present the means ± SEM (N=3). (B) SRA 
expression with DHT (10nM) treatment or caAck1 activation in LNCaP cells. RNA was isolated 
and real-time qRT-PCR was done to analyze SRA RNA levels. Values present the means ± SEM 
(N=3). (C and D) SRA knockdown abrogates the interaction between AR and SLIRP. (C) 
LNCaP cells were transfected with caAck1 with or without SRA-siRNA (50nM). (D) LNCaP 
cells were transfected with SRA-siRNA (50nM), with or without DHT (10nM). (E) Ack1 
activation does not affect the association between SRA-SLIRP and SRA-AR in LNCaP cells by 
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IP-RT-PCR. (F) DHT (10nM) increases the association between SRA-AR but not SRA-SLIRP in 
LNCaP cells. These experiments were done by Dr. Zhentao (Richard) Zhang, in collaboration. 
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Figure 2.4: Validation of SLIRP knockdown by siRNA 
(A). Three different siRNAs from Invitrogen were tested and protein knockdown assayed in 
LNCaP cells. (B) A pool of SLIRP siRNA (40nM) was tested in cytoplasmic vs. nuclear 
extraction of LNCaP protein lysates. 
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Figure 2.5: Effects of SLIRP on AR mediated transcriptional activity in LNCaP cells.  
(A) SLIRP over-expression represses AR transactivation in a dose dependent manner in LNCaP 
cells co-transfected with AR, ARR2PB-Luciferase, and SLIRP for 24hrs and then treated with 
1nM DHT or vehicle control for another 24hrs. Values present the means ± SEM (N=3). (B) 
SLIRP knockdown increases AR transactivation in a dose dependent manner in LNCaP cells co-
transfected with AR, ARR2PB-Luciferase, and SLIRP-siRNA for 24hrs and treated with 1nM 
DHT or vehicle control for another 24hrs. Values present the means ± SEM (N=3). (C) SLIRP 
knockdown (40nM) increases AR mediated transcriptional activity of PSA and hK2 in LNCaP 
cells.  
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Figure 2.6: Effects of DHT and Ack1 activation on SLIRP recruitment to androgen 
response element (ARE). (A) DHT treatment impairs the recruitment of SLIRP to ARE on PSA 
and hK2 enhancer region. LNCaP cells were treated with DHT (10nM) for a period of time as 
indicated in SFM. ChIP analysis for AR and SLIRP binding to ARE enhancer of the PSA gene 
and hK2 gene were performed by using quantitative PCR. (B) AR antagonist casodex does not 
affect SLIRP recruitment on PSA and hK2 enhancer while Ack1 activation by heregulin impairs 
SLIRP recruitment to ARE. LNCaP cells were treated with DHT (10nM), casodex (5µM), 
heregulin (10 ng/ml), or vehicle control for 2 hrs. ChIP analysis for AR and SLIRP binding to 
ARE enhancer were performed by using quantitative PCR. These experiments were done by Dr. 
Yuanbo Liu, in collaboration. 
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Figure 2.7: Current model of Ack1 activation and DHT treatment on AR-SLIRP 
interaction. In the absence of Ack1 activation and DHT, the co-repressor SLIRP binds to AR 
and is recruited to ARE of AR target to suppress gene expression. With the activation of Ack1 or 
DHT treatment, the association between AR and SLIRP is abrogated and AR dependent 
transcription is initiated. 
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CHAPTER III: SLIRP ACTS AS A POTENTIAL TUMOR SUPRESSOR IN 
PROSTATE CANCER CELLS BY REGULATING CELL CYCLE 
 
3.1 Overview 
  
Mechanisms underlying AR reactivation in CRPC is not well understood. We have 
demonstrated that SLIRP forms a co-repressor complex with AR and controls AR dependent 
transcription. In addition, Ack1 can dissociate this co-repressor complex and activate AR 
signaling. Thus, SLIRP repression of the AR signaling pathway may be a mechanism that is 
undermined in late stage prostate cancer. We wanted to understand the effect of the loss of 
SLIRP on prostate cancer biology. We preformed RNA-seq analysis to examine gene expression 
changes with the loss of SLIRP. Interesting, we saw a broad global change in gene expression 
with SLIRP knockdown. When we used a published AR gene signature set to compare our 
knockdown samples to control, we identify a clear partitioning of our samples validating the 
significance of SLIRP in prostate cancer. Using our RNA-seq data, we generated a 176 AR gene 
signature which separated genes into three distinct classes. A closer look into the pathways 
affected by SLIRP knockdown led us to study cell cycle regulation, a hallmark of cancer, as 
many proteins in this pathway were changed. Androgens increase cell proliferation by advancing 
cells through the cell cycle. We find that SLIRP knockdown affect cell cycle regulators including 
phospho-Rb, E2F1, E2F2, CDK4, cyclin B1, and cyclin A2. This phenomenon is further 
illustrated with an increase of LNCaP cells in S-phase with SLIRP knockdown. Consequently, 
this supports the role of SLIRP as a tumor suppressor that can regulate cell cycle progression in 
part through regulation of AR signaling.  
3.2 Introduction  
Patients with metastatic disease undergo androgen deprivation therapy which leads to 
castration resistant prostate cancer (CRPC). CRPC is a terminal disease which arises with the 
  
  55 
resurgence of androgen receptor (AR) activity. AR gene amplification, AR mutations, 
deregulation of co-activators/co-repressors, and alterations in upstream AR signaling pathways 
all may contribute to the re-emergence of AR activity in CRPC. Furthermore, other signaling 
mechanisms like transcription factors, oncogenes, and tumor suppressors are altered in prostate 
cancer and contribute to the development of CRPC. Thus understanding the interplay between 
AR and other signaling networks and their involvement in metastatic CRPC is important in 
developing proper therapeutic agents. 
One hallmark of cancer cells is the ability to bypass cell cycle checkpoints and induce 
uncontrolled cell division. Androgens and the androgen receptor have also been shown to be 
important in cell cycle in androgen dependent cells. Cells in resting phase, G0, are regulated by 
retinoblastoma protein (Rb) to prevent unplanned cell cycle progression. Androgens can 
stimulate the progression of cell cycle by the up-regulation of cyclins and cyclin-dependent 
kinase (CDKs) which lead to coordinate activation of CDK/cyclin complexes. Cyclin D1 
accumulation and subsequent binding to CDK4/6 result in phosphorylation of Rb and partial 
inactivation. Further interaction of CDK2 with cyclin A and E results in complete inactivation of 
Rb and progression of the cell cycle. Consequently, cyclin D1 can contribute to the inhibition of 
AR activity by direct binding to the N-terminus independent of CDK activity [125, 126]. In 
addition, AR in CRPC regulates genes that control transition into and out of mitosis like UBE2C 
which is required for CRPC cell growth [127]. It has also been demonstrated that when prostate 
cancer cells are deprived of androgen, they arrest in early G1 and show reduced cyclin D1 and 
hypophosphorylated Rb protein levels [55, 56]. Furthermore, androgens can induce cyclin D1 
expression via mTOR pathway which promotes the translation of cyclin D1 and increases cyclin 
D1 protein levels [56].  
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Thus a dynamic interplay exists between androgens, AR, and the cell cycle in prostate 
cancer. We have shown that SLIRP acts as a co-repressor of AR signaling and it dissociates 
when AR is activated. Gene expression analysis using RNA-seq with SLIRP knockdown 
demonstrated a change in the global gene expression profile compared to control. Multiple AR 
dependent genes showed an increase with SLIRP knockdown. Furthermore, we generated an AR 
gene signature that was used to cluster our samples and illustrated generation of three classes of 
genes. These three classes represent one set that is more SLIRP dependent and SLIRP loss 
reduces expression of these genes, a group where SLIRP knockdown has a greater impact on the 
up-regulation of the genes, and a group that is more androgen dependent than SLIRP dependent. 
Analysis of pathways using gene list created by significance analysis of microarray (SAM) on 
our RNA-seq data, directed us to a role of SLIRP in cell cycle regulation that is AR dependent. 
SLIRP knockdown stimulates an increase in cyclin and CDK levels with hyperphosphorylation 
of Rb.  Flow cytometry analysis showed an increase of cells in S-phase with SLIRP knockdown 
compared to control. Furthermore, the role of SLIRP in cell cycle seems to be AR dependent as 
AR negative cells did not demonstrate this feature. The effect of AR co-repressors NCoR1 and 
SMRT knockdown on cell cycle did not demonstrate the enhanced cell cycle progression seen 
with SLIRP knockdown. SHARP co-repressor knockdown showed modest enhancement of cell 
cycle but not to the degree of SLIRP knockdown. Hence, the loss of SLIRP in conjunction with 
AR signaling may provide a mechanism by which cell cycle progression is enhanced and 
regulation bypassed. 
3.1 Materials and Methods 
Cells and reagents -LNCaP cells, PC3, DU145, and HEK 293T cells were obtained from 
the American Type Culture Collection (Manassas, VA, USA). LAPC4 cells were a gift from the 
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Charles Sawyers lab. DHT was acquired from Sigma (Sigma-Aldrich, St Louis, MO, USA). 
Short tandem repeat (STR) authentication of LNCaP and LAPC4 cell lines were conducted 
(UNC Tissue Culture facility). A mouse monoclonal antibody against AR (F39.4.1, Biogenex, 
San Ramon, CA, USA) was used for immunoblotting. Antibody against SLIRP (#ab51523) was 
purchased from Abcam (Cambridge, MA, USA). Antibodies against total ERK (#9102), 
phospho-specific ERK (#9101), and phospho-Rb (Ser 807/811, #9308P) were obtained from Cell 
Signaling Technology (Beverly, MA, USA). Rb (C-15), CDK2 (M2), and CDK4 (DCS-35) 
antibodies were purchased from Santa Cruz (Santa Cruz Biotechnology Inc., Santa Cruz, CA). 
Pan-Actin Ab-5 (ACTN05) was acquired from Neomarkers (Fremont, CA). Custom nonsense 
control (NS) siRNA (GUUCAGGUCGAUAUGUGCA), SMARTpool NCoR1 siRNA (L-
003518-00), SMARTpool NCoR2/SMRT siRNA (L-020145-01) were purchased from 
Dharmacon (Thermo Scientific Dharmacon, Pittsburg, PA). Pool mix of SLIRP siRNA 
(HSS130109, HSS188666, HSS188667) and SHARP/SPEN siRNA (HSS118024, HSS118025, 
HSS118026) were obtained from Invitrogen (Life Technologies, Grand Island, NY) and AR 
siRNA sequences were custom designed (Mol Cancer Ther April 2005 4:505-515) 
Plasmids-The plasmids encoding Fl-WT-AR were described before (Mahajan NP, Proc 
Natl Acad Sci U S A, 2007. 104(20): p. 8438-43), (Mahajan NP, Cancer Res, 2005. 65(22): p. 
10514-23). FLAG-SLIRP and SRA expressing vector were purchased from Origene Inc. 
(Rockville, MD, USA).  
siRNA Transfection- Cell lines were transfected with custom nonsense control siRNA 
or target siRNA. A pool of SLIRP siRNA, pool of AR-siRNA, SRA siRNA, a pool of SHARP 
siRNA, NCoR1 siRNA, or NCoR2/SMRT siRNA was used for the appropriate experiments. The 
siRNA was transfected at 40nM for 24hrs in charcoal stripped media. Cells were washed once 
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with 1x PBS and replaced with serum free media containing EtOH or 0.1nM, 1nM, 10nM DHT 
for another 24hrs.  Cells were isolated as needed for the appropriate experiments. 
Quantitative Real-time PCR- LNCaP cells were transfected with custom nonsense 
control siRNA or target siRNA. A pool of SLIRP siRNA, a pool of SHARP siRNA, NCoR1 
siRNA, or NCoR2/SMRT siRNA was used for the appropriate experiments. The siRNA was 
transfected at 40nM for 24hrs. Cells were washed once with 1x PBS and replaced with serum 
free media containing EtOH or 0.1nM, 1nM, 10nM DHT for another 24hrs. RNA was collected 
using Qiagen RNeasy kit (74104) and cDNA was generated using Biorad iscript cDNA synthesis 
kit (Bio-Rad Laboratories, Hercules, CA). Real-time PCR was conducted using GAPDH (probe-
FAM-CAGCCTCAAGATCATCAGCAATGCCTC-BHQ, Fp-
GTCATGGGTGTGAACCATGAGA, Rp-GGTCATGAGTCCTTCCACGATAC), PSA (probe-
FAM-ATGACGTGTGTGCGCAAGTTCACCC-BHQ, Fp-GTTTTTGCCTGGCCCGTAG, Rp-
GCATGAACTTGGTCACCTTCTG), hK2 (probe-TGACCTCATGCTGCTCCGCCTGT, Fp-
GCCTTAGACCAGATGAAGACTCCA, Rp-GCCCAGGACCTTCACAACATC), SLIRP 
(probe-CGGCCATGTCAGAAGGTGCA, Fp-GCGCTGCGTAGAAGTATCAA, Rp-
ACTGAACCCAACCCAAACCT), SHARP (Probe-TCGCCCCTTGGATGAAAGGA, Fp-
CAGCATGGATAGGTCCAGAA, Rp-CTGGAAGATGTTGCGAAGGT), CCNA2 (Probe-
TGGTCCCTCTTGATTATCCAATGGA, Fp-TACCTGGACCCAGAAAACCA, Rp-
CCATTTCCCTAAGGTATGTGTGA), CCNB1(Probe-
CAAATTGCAGCAGGAGCTTTTTGC, Fp-TGGTGCACTTTCCTCCTTCT, Rp-
TCTTAGCCAGGTGCTGCATA), CCND1 (Probe-AGCCCGTGAAAAAGAGCCGC, Fp-
AACTACCTGGACCGCTTCCT, Rp-CCACTTGAGCTTGTTCACCA), CCND2 (Probe- 
CCGCGGAGAAGCTGTGCATT, Fp- GTGCTGTCTGCATGTTCCTG, Rp- 
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TCCTGAGGCTTGATGGAGTT), CCND3 (Probe- GGAAGTCTTCCCCCTGGCCA, Fp- 
AGTTGCGGGTATGTGAGGAG, Rp- AGCTGCAACTGCGCCTTTC), CCNE1 (Probe- 
GGCTCCCCGCTGCCTGTACT, Fp- CCTCGGATTATTGCACCATC, Rp- 
CTGCAGAAGAGGGTGTTGCT), CCNE2 (Probe- GGCCAAGAAGAGGAAAACTACCCA, 
Fp- CCCCAAGAAGCCCAGATAAT, Rp- TACAGGTGGCCAACAATTCC), CDK1 (Probe-
CCCAAATGGAAACCAGGAAGCC, Fp-TGGCCAGAAGTGGAATCTTT, Rp-
CCATTTTGCCAGAAATTCGT), CDK2 (Probe-TGGGGACCCCAGATGAGGTC, Fp-
ACCAGCTCTTCCGGATCTTT, Rp-CATCCTGGAAGAAAGGGTGA), CDK4 (Probe-
GCTGACTTTGGCCTGGCCAG, Fp-GTGGTGGAACAGTCAAGCTG, Rp-
CCACAGAAGAGAGGCTTTCG), CDK6 (Probe-CCCGCGACTTGAAGAACGGA, Fp-
GCCTATGGGAAGGTGTTCAA, Rp-TGCACACATCAAACAACCTG), E2F1 (Probe- 
TGAAGCGGAGGCTGGACCTG, Fp- ACCCTGACCTGCTGCTCTT, Rp- 
CTCTCGGCCAGGTACTGATG), and E2F2 (Probe- GGCCAAGTTGTGCGATGCCT, Fp- 
CCTACTACACACCGCTGTACCC, Rp- CCAGATCCAGCTTCCTTTTG) sets.  
Western-LNCaP cells were transfected with control NS, SLIRP, SHARP, NCoR1, 
SMRT, or AR siRNA for 24hrs. Cells were lysed with RIPA protein lysis buffer and extracts 
were quantified by Bradford assay (Bio-Rad Laboratories, Hercules, CA) and analyzed by SDS-
PAGE as previously described (Steinbrecher et al., Mol Cell Biol 25, 8444-8455). Samples were 
blotted for AR, SLIRP, pan-actin, p-Rb, Rb, CDK2, CDK4, CCND1, p-ERK, or ERK. 
RT-PCR- LNCaP cells were transfected with control NS, SLIRP, SHARP, NCoR1, or 
SMRT siRNA for 24hrs in charcoal stripped media. Media was changed to serum free media 
(SFM) with vehicle (EtOH) or 1nM DHT for 24hrs. RNA was extracted using RNeasy kit 
(Qiagen, Valencia, CA) and RT conducted using iscript cDNA synthesis kit (Biorad, Hercules, 
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CA). PCR was conducted using GAPDH as control and SLIRP, SHARP, NCoR1, and SMRT 
primers.  
Cell cycle analysis- LNCaP cells were transfected with nonsense control or SLIRP pool 
siRNA, SHARP pool siRNA, NCoR1, or SMRT siRNA at 40nM for 24hrs in charcoal stripped 
media. Media was changed to SFM with vehicle (EtOH), 0.1nM, 1nM, or 10nM DHT for 24hrs. 
Cells were than incubated for 2hrs with BrdU at 10ng/ml. Cells were processed according to 
protocol (Nuclei Propidium Iodide Staining Procedure for DNA/Cell Cycle Analysis Revised 
June 15, 1993 by Ben Poulose and June 13, 1994 by Laura Byrd; Kastan, MB et al, Cancer 
Research 51:6304-6311, White RA et al, Cytometry 11:314-317). Briefly, cells were washed 
with PBS, and fixed with 100% EtOH O/N at -20. Then, cells were treated with 0.08%pepsin, 
2N HCL, 0.1M sodium borate, and washed with IFA+0.5% Tween. Cells were incubated with 
anti-BrdU (Invitrogen, 1:20) overnight at 4C. Propidium iodide was added, cells were filtered for 
single cell suspension before analysis, and samples were run on Cyan (Beckman-Coulter (Dako), 
Brea, CA). 
Cell Proliferation assay- LNCaP cells were transfected with nonsense control, SLIRP 
pool siRNA (40nM), SHARP, NCoR1, or SMRT siRNA for 24hrs in charcoal stripped media. 
Media was changed to SFM with vehicle (EtOH) or 1nM DHT for 1-5 days. WST/CCK-8 
(Dojindo Inc, Rockville, MD) was added at 10ul/well and incubated 1-2hrs. Cells were read at 
Abs 440nm using Synergy 2 (Biotek, Winooski, VT) plate reader each day. 
RNA-seq- LNCaP cells were transfected with custom nonsense control siRNA or a pool 
of SLIRP siRNA (HSS130109, HSS188666, HSS188667 Invitrogen, Carlsbad, CA) at 40nM for 
24hrs. Cells were washed once with PBS and replaced with SFM containing EtOH or 1nM/ml 
DHT for another 24hrs. RNA was collected using RNeasy kit (Qiagen, Valencia, CA). RNA 
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concentration was checked by Nanodrop and quality assayed by Bioanalyzer. RNA sequencing 
was conducted by the HTSF core at UNC and aligned and normalized by the Bioinformatics core 
at UNC. Resulting dataset was analyzed by SAM and the up/down regulated gene list generated 
with an FDR ≤ 1 were used in DAVID functional software (Nature Protocols 2009; 4(1):44 & 
Nucleic Acids Res. 2009;37(1):1) and Ingenuity to generate pathway maps (IPA, QIAGEN 
Redwood City, www.qiagen.com/ingenuity). Gene lists were also generated for AR and SLIRP 
gene signature using Significance analysis of microarray (SAM, Stanford University, Tusher, 
Tibshirani and Chu (2001), http://statweb.stanford.edu/~tibs/SAM/) by comparing NS-vehicle 
versus NS-1nM DHT and NS-vehicle versus SLIRP-siRNA-vehicle respectively. Heatmap was 
generated by using Cluster (Stanford University) and Java Treeview (Sourceforge).  
Statistical Analysis- Statistical analysis was performed using Student's t test using 
Graphpad prism. 
3.4 Results  
RNA-seq analysis shows the effect on AR signaling 
We initially preformed gene expression profiling using microarray on SLIRP knockdown 
with DHT treatment on LNCaP cells (Fig 5.1). Preliminary analysis of our microarray data 
encouraged us to pursue further validation by RNA-sequencing (RNA-seq). LNCaP cells were 
transfected with SLIRP siRNA and treated with vehicle or 1nM DHT. Validation of SLIRP 
knockdown in our replicate samples was verified by real-time (Fig 3.1A). SLIRP knockdown 
alone enhanced PSA levels between 1.5-2 fold while hK2 levels increased 2.5-3 fold compared 
to our control further validating our samples for RNA-seq analysis. RNA transcript analysis 
using Cluster filtering software and heatmap generation of the RNA-seq data differentiated our 
control samples with or without DHT versus our SLIRP knockdown samples with or without 
DHT (Fig 3.1B). We demonstrate formation of a distinctive differential gene expression profile 
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of the SLIRP knockdown samples compared to our control samples (Fig 3.1B) SAM analysis of 
the raw transcripts comparing all our control samples (vehicle and DHT) to all our SLIRP 
samples revealed over 2000 genes that were up-regulated and over 1500 genes down-regulated 
with a false discovery rate (FDR) of ≤ 1% (Fig 3.1C). The up-regulated and down-regulated gene 
lists generated from SAM was applied to David functional annotation analysis to identify 
pertinent biological functions altered. Relevant functions/pathways such as cell cycle and 
phosphoprotein were significantly affected as denoted by the Benjamini values (corrected p-
value) (Fig 3.2A). Ingenuity analysis (IPA) highlighted Cancer as well as molecular functions 
cell death and survival and cell cycle as highly affected by SLIRP knockdown (Fig 3.2B).  
 We utilized our RNA-seq data to identify which genes are androgen regulated and 
generated a gene signature. Comparing only the NS vehicle control to NS DHT treated samples 
in SAM, we identified 176 genes that were up-regulated with an FDR of 4.7% (Appendix Table 
5.1). There were no down-regulated genes identified with an FDR of less than 5%. Applying this 
AR gene signature to all of our samples from RNA-seq, we demonstrate a separation of our 
samples by both control versus SLIRP knockdown and DHT treatment (Fig 3.3A).  Furthermore, 
three subclasses of genes were generated (Fig 3.3A, Appendix Table 5.1). The first class of 
genes (C1) are repressed by SLIRP knockdown, indicating that SLIRP is important for the 
activation of these genes. The second class (C2) is regulated by SLIRP and loss of SLIRP results 
in the up-regulation of these genes. This class is the largest of the three classes where SLIRP 
knockdown has a greater effect on the up-regulation of these genes than DHT. We have shown 
that SLIRP acts as a co-repressor of AR and the loss of SLIRP could lead to increases in AR 
target gene expression as indicated by the C2 class of genes. The last class of genes (C3) is 
predominately regulated by DHT treatment and SLIRP knockdown has a relatively smaller effect 
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on their expression. Different studies have identified varying AR gene signatures from as low as 
27 genes to over 300 [128-130]. However, the classification of distinct subclasses due to our 
SLIRP knockdown samples has not been found previously. Therefore, this AR gene signature 
could potentially be important in characterizing tumors and used for stratifying patients to the 
most effective treatments. 
To further validate our RNA-seq data, we used an AR gene signature previously 
published consisting of approximately 267 genes [130]. We found that our RNA-seq data only 
contained 247 genes of the originally published 267 AR gene signature. Gene signatures can 
vary and rarely do multiple gene signatures contain the same number and set of genes. We 
applied this AR gene signature to our data and clustering analysis demonstrates a separation of 
the control samples and SLIRP knockdown samples (Fig 3.3B). We also distinguish the three 
classes of genes found in our AR gene signature as well as an additional class where DHT down-
regulates the genes. We examined the data for SLIRP regulated genes by comparing our NS-
vehicle treated samples to SLIRP-knockdown vehicle treated samples and generated a SLIRP 
gene signature. SAM analysis of these groups identified 887 up-regulated genes (FDR 0.54%) 
and 875 down-regulated genes (FDR 4.79%) (Fig 3.3C, Appendix Table 5.2). Applying the 
SLIRP gene signature to all of our RNA-seq samples demonstrated a difference between our NS 
samples and SLIRP knockdown samples. The vehicle and DHT samples clustered randomly 
among the two groups indicating DHT had little influence in this gene signature. The large 
SLIRP gene signature implies that pathways other than AR are affected by SLIRP knockdown 
and thus SLIRP may have a broader role than initially assumed. 
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SLIRP functions in cell cycle by regulating key components 
Androgens/AR can enhance cell cycle regulators and thus cell cycle progression. In turn, 
the up-regulation of cyclins and CDKs enhances or inhibits AR thereby creating a 
negative/positive feedback loop [57]. We pursued the cell cycle pathway since SLIRP 
knockdown affected gene expression of cell cycle components according to the RNA-seq 
analysis. First, we used our pool SLIRP siRNA to examine the phosphorylation levels of Rb 
protein. Rb inhibits G1-S transition and phosphorylation of Rb by cyclin D1/CDK4/6 and cyclin 
E/CDK2 complexes leads to its inactivation and subsequent transition from G1 to S phase. We 
demonstrate that our SLIRP siRNA pool in LNCaP cells enhance Rb phosphorylation (Fig 
3.4A). In addition, Rb protein phosphorylation shows a biphasic response to DHT as a high dose 
of 10nM DHT reduces Rb phosphorylation (Fig 3.4A). Furthermore, we show increases in cyclin 
D1 and CDK4 protein levels which are important in phosphorylating Rb and inducing transition 
from G1 to S phase (Fig 3.4A). Further evidence for the role of SLIRP in cell cycle was 
supported by the enhancement of cell proliferation of LNCaP cells compared to control (Fig 
3.4B). Moreover, real-time PCR demonstrates mRNA levels of multiple cyclins and CDKs 
increase with SLIRP knockdown (Fig 3.4C). In addition, flow cytometry analysis of cell cycle by 
BrdU incorporation into new synthesized DNA of cells demonstrates that SLIRP knockdown 
increases the amount of cells in S-phase (Fig 3.4D). We demonstrate that cells with SLIRP 
knockdown (-DHT) have ~3 fold increase of cells in S-phase compared to control (Fig 3.4D). In 
cell cycle analysis, the increase in S-phase cells seems additive with DHT and SLIRP 
knockdown rather than synergistic. SLIRP regulates the G1 to S transition and loss of SLIRP 
contributes to the unregulated proliferation that is a hallmark of cancer cells.  
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SLIRP regulation of cell cycle is AR dependent 
We examined whether the effect of SLIRP knockdown on cell cycle was an independent 
function of SLIRP or a function of the SLIRP-AR signaling complex. We used another AR 
positive cell line LAPC4 and AR negative PC3 and DU145 cells. LAPC4 is another prostate 
cancer cell line, derived from a metastatic lymph node, that contains wild-type AR, and is 
androgen responsive [131]. The PC3 cell line derived from a bone metastasis, and DU145, 
generated from a brain metastasis fail to express AR RNA and are androgen independent [132, 
133]. We found that LAPC4 recapitulated the effect of SLIRP knockdown on phospho-Rb (p-
Rb) protein levels (Fig 3.5A). However, p-Rb did not increase with SLIRP knockdown in PC3 
cells (Fig 3.5A). DU145 cells contain an exon 21 deletion in the Rb gene which abolishes it’s 
function [134]. SLIRP knockdown modestly increased proliferation in LAPC4 cells (significant 
p≤0.004 at day 4) although not as strongly as in LNCaP cells (Fig 3.5B). This may be due to the 
difficulty in transfecting this cell line and thus variation in knockdown efficiency and further 
optimization of knockdown may be needed. SLIRP knockdown did not increase cell proliferation 
in PC3 and DU145 cells (Fig 3.5B). SLIRP knockdown minimally increased mRNA levels of 
cyclinA2, CDK2, and CDK6 in LAPC4 but not to the extent seen in LNCaP cells (Fig 3.5C). 
SLIRP knockdown appeared to be low at 20-30% and may account of the minor change in 
cyclin/CDK levels. There was no increase in the mRNA levels of cyclins and CDKs with SLIRP 
knockdown in PC3 and DU145 cells except with CDK6 (Fig 3.5C). We note that there is 
disparity in SLIRP knockdown between protein levels and mRNA which may be due to long 
half-life or a compensatory increase of mRNA into protein resulting in minimal reduction in 
protein levels. The effect of SLIRP knockdown on cell cycle correlates with AR expression and 
thus there may be a requirement for AR in cell proliferation.  
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SHARP affects cell cycle but not NCoR1 and SMRT co-repressors 
We also determined if other AR co-repressors play a role in cell cycle or whether it’s 
specific to SLIRP. NCoR1 and SMRT are direct AR interactors that inhibit AR signaling. 
SHARP binds to the same stem-loop as SLIRP on SRA and represses steroid receptor signaling. 
Knockdown of NCoR1 did not increase p-Rb levels (Fig 3.6A). In contrast, SMRT knockdown 
showed a modest increase in p-Rb levels (Fig 3.6A). We demonstrate that SHARP knockdown 
alone illustrated modest increase in p-Rb protein levels although not to the extent of SLIRP 
knockdown (Fig 3.6A). Furthermore, p-Rb levels of SHARP knockdown with DHT treatment 
were comparable to SLIRP knockdown alone (Fig 3.6A). As expected, AR and SRA knockdown 
did not affect p-Rb levels (Fig 3.6A). SRA acts as a scaffold that can interact with both co-
activators and co-repressors so the effect is reflected by the net effects on SRA’s interacting 
partners. Analysis of cell proliferation showed no change in proliferation with NCoR1 or SMRT 
knockdown (Fig 3.6B). Surprisingly, we did not see an effect of SHARP knockdown on cell 
proliferation (Fig 3.6B). SHARP knockdown also increased mRNA levels of cyclin A2, cyclin 
B1, CDK1, and CDK2 but not to the degree of SLIRP knockdown (Fig 3.6C). Flow cytometry 
analysis of cell cycle phases with NCoR1 knockdown did not affect the percentage of cells in S-
phase compared to control (Fig 3.6D). SMRT knockdown demonstrated a nominal increase of 
cells in S-phase (Fig 3.6D). SHARP knockdown illustrated an increase in S-phase about 3-fold 
compared to control (Fig 3.8D). Both SHARP and SLIRP bind SRA and share homology in their 
RRM domain and thus may interact with similar partners. As well, SLIRP and SHARP co-
transfection repressed ER transactivation in an additive fashion [105]. Though we saw an 
increase in both Rb phosphorylation and S-phase entry, we did not see an increase in cell 
proliferation with SHARP knockdown. We speculated whether an increase in apoptosis could 
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account for the cell proliferation results. Analyzing the flow data for apoptosis (propidium iodide 
staining), we found a negligible increase in apoptosis with SLIRP knockdown but a 3 fold 
increase with SHARP, NCoR1, and SMRT (Fig 3.6E). The apoptosis data may explain why we 
did not observe an increase in the proliferation experiments. SLIRP plays the central role in cell 
cycle regulation and may recruit SHARP to facilitate regulation.  
3.5 Discussion  
We have established a role for SLIRP as a co-repressor in AR signaling. Furthermore, we  
investigated the importance of SLIRP loss in AR signaling and prostate cancer biology by gene 
expression profiling. We utilized RNA-seq to understand the changes in gene expression profile 
of androgen dependent prostate cancer cell line LNCaP with androgen treatment and SLIRP 
knockdown. First, we show that SLIRP loss results in changes in gene expression for a large set 
of genes in RNA-seq demonstrating a broad global change in expression. This is evident when 
the gene lists obtained through SAM analysis with an FDR ≤ 1 is applied to DAVID and 
Ingenuity pathway analysis (IPA) illustrating changes in multiple biological functions with very 
significant Benjamnini and p-values. In addition, we found a large SLIRP signature that was 
independent of DHT as they clustered randomly with vehicle. Though SLIRP regulates AR 
signaling, the SLIRP signature infers SLIRP could regulate additional pathways besides AR. The 
AR gene signature contained many of the canonical AR genes like PSA, hK2, TMPRSS2, and 
FKBP5. We also demonstrate that subclasses of genes can be generated using the AR gene 
signature implying distinctive SLIRP regulation of AR dependent genes. Notably, we show that 
NKX3.1 resides in the C1 subclass which is down-regulated with SLIRP knockdown. NKX3.1 
loss leads to hyperplasia and PIN development in mice [22, 23]. Therefore, the loss of SLIRP 
could lead to reduced NKX3.1 and augment prostate cancer development. As well, the effect of 
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DHT on the large C2 subset of genes ends up being overshadowed by SLIRP knockdown 
demonstrating the importance of loss of SLIRP in the up-regulation of these genes. Thus, SLIRP 
seems to play a role in multiple pathways that have not been identified yet.. 
Secondly, we saw profound changes in the cell cycle pathway which was one of the top 5 
pathways perturbed in both DAVID and IPA with SLIRP knockdown. Rb is an important 
gatekeeper of cell division. However, in many cancers, Rb function is inactivated leading to a 
major characteristic of a cancer cell, uncontrolled proliferation. We found that SLIRP 
knockdown results in increased Rb phosphorylation in a dose dependent manner in LNCaP cells. 
It has been previously described that DHT has a biphasic response where high doses can inhibit 
proliferation and induce differentiation markers [135, 136]. We found that cyclin D1 protein 
increased but was unaffected at the mRNA level by SLIRP knockdown. It has been shown that 
the Cyclin D family is unaffected by the presence or absence of androgen at the mRNA level 
[57]. However Cyclin D1-D3 protein levels can be increased by the mTOR pathway which can 
be induced by AR signaling [56]. Though we demonstrate increases in cyclin D1 and CDK 4 
protein levels with SLIRP knockdown, it will be necessary to investigate the other G1 cyclins 
that include the cyclin D and E family. Interestingly, we found that E2F 1 and E2F2 levels were 
sensitive to SLIRP knockdown and increased substantially. E2F1 regulates the AR locus and 
cyclin A as well as responding biphasically to DHT [135, 137]. Thus, the increase of cyclin A2 
levels could be a response to the increase in E2F levels with SLIRP knockdown. Therefore, the 
release of E2F from Rb enhances AR expression and cell cycle progression via cyclins. Because 
E2F response to SLIRP knockdown is sensitive, it would be important to investigate SLIRP 
regulation of E2F expression..  
  
  69 
SLIRP regulation of cell cycle is in part dependent on AR signaling. Whereas AR 
positive lines LNCaP and LAPC4 showed increased Rb phosphorylation and increased cyclin-
CDK levels (protein and RNA), we saw no change in AR negative cells PC3 and DU145. 
LAPC4 proliferation assay and qRT-PCR showed moderate change with SLIRP knockdown. 
LAPC4 cells are patchy and grow in circular foci which make them more difficult to transfect 
than LNCaP cells and thus only demonstrate moderate changes in the assays. Another possibility 
is that the proliferation assay may not be sensitive enough to detect changes in proliferation 
because LAPC4 cells are androgen dependent and the assays are conducted in androgen absent 
media. Therefore, a more real-time based assay such as RTCA (real-time cell analyzer) to 
determine proliferation could be attempted. Nonetheless, we demonstrate that SLIRP knockdown 
in LNCaP and LAPC4 increase p-Rb levels and induce S-phase entry (data not shown for 
LAPC4) and enhance cell cycle. Interestingly, we found CDK6 levels increase in PC3 and 
DU145 implying that increase in CDK6 maybe independent of AR. CDK6 has been shown to 
directly bind AR and enhance activity independent of cyclin D1 and its role in cell cycle [62]. 
Therefore, one can postulate that CDK6 may also have a cell cycle independent role in these AR 
negative cell lines. 
There are other unknown interactors of SLIRP that could participate in the regulation of 
cell division. Thus, there is the possibility that the role of SLIRP in cell cycle regulation is 
independent of the AR pathway and the affect we are seeing in AR positive versus AR negative 
cell lines is an indirect result of SLIRP knockdown. Further validation that AR is partly 
responsible for cell cycle progression with SLIRP loss could be ascertained by using AR specific 
antagonist MDV3100 or to knockdown AR with siRNA and determine p-Rb levels. We would 
also need to determine whether SLIRP and AR directly interact or indirectly through other co-
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factors. Identifying components in the AR-SLIRP complex could shed light to the mechanism 
behind SLIRP regulation of AR as well how SLIRP regulates cell division.  
Additionally, the increased Rb phosphorylation was not seen when we investigated two 
other direct AR co-repressors, NCoR1 and SMRT. NCoR1 and SMRT act independently of their 
HDAC function and bind AR preferably in the presence of agonist or antagonist resulting in 
inhibition. We found that NCoR1 knockdown did not affect p-Rb levels while SMRT 
knockdown showed a moderate increase. One reason for NCoR1 and SMRT not affecting cell 
cycle is that they are not RNA binding proteins and SRA interaction may be important in cell 
cycle regulation. SRA acts as a scaffold which recruits SLIRP and SHARP to nuclear receptors. 
Furthermore, NCoR1 and SMRT repression of AR functions best when AR is bound by agonists 
or antagonists [95, 96, 98]. Hence, a complex is formed with SRA, SLIRP and other cofactors 
that represses AR dependent signaling that is absent in NCoR1 and SMRT interaction with AR. 
In contrast, we saw an effect on cell cycle with knockdown of co-repressor although not to the 
extent of SLIRP knockdown. One potential explanation is that SLIRP mainly consists of a RRM 
domain with substantial homology to SHARP. Since, both co-repressors have high homology 
and can both bind RNA binding protein SRA unlike NCoR1 and SMRT, we could ascertain that 
they behave similarly. Thus, SRA could play a very important role in recruiting other co-
repressors besides SLIRP that is involved in the regulation of AR signaling, cell cycle, or both.  
 Collectively, we have shown the importance of SLIRP in gene regulation. We 
have found that SLIRP loss in concert with AR signaling can promote cell cycle progression. 
Though we have found a major function of SLIRP in cell cycle, there were multiple other 
pathways that were significantly affected. Hence, we define a role for co-repressor SLIRP as a 
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tumor suppressor which regulates AR and many other pathways. Its’ function in other pathways 
would help to define how it has such a broad effect on a massive set of genes.  
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Figure 3.1: RNA-seq Heatmap and SAM on LNCaP cells with SLIRP knockdown 
(A) qRT-PCR validation of SLIRP knockdown and enhanced PSA and hK2 mRNA levels prior 
to RNA-seq analysis of samples. Indicated samples (2 from each group per experiment) were 
taken for RNA-seq. (B) Heatmap clustering of samples with SAM plot. (C) Venn diagram of 
genes obtained from SAM analysis of all NS samples versus all SLIRP samples with an FDR of 
≤ 1.  
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Figure 3.2: David and Ingenuity analysis of RNA-seq data 
(A) David functional annotation on gene list obtained through SAM analysis of NS vs. SLIRP 
samples. Functions like Cell cycle in the upregulated gene list and intracellular transport in the 
down-regulated gene list were significantly affected as shown by the Benjamini numbers that 
were obtained. (B) IPA on the combined up and down-regulated gene list from SAM illustrates 
similar networks like cell cycle and replication.  
 
 
  
  76 
 
 
 
  
  77 
 
 
 
 
  
  78 
 
 
Figure 3.3: Gene Signatures from RNA-seq data 
(A) Heatmap of 176 AR gene signature obtained from NS-Vehicle vs. NS-1nM DHT. Signature 
clusters samples by both knockdown and treatment. Signature forms three subclasses of genes. 
(B) Heatmap of published AR gene signature (Mendiratta et al 2009) applied to RNA-seq data. 
Data forms four subclasses of genes. (C) SLIRP gene signature obtained from SAM analysis of 
NS-Vehicle vs. SLIRP-siRNA-Vehicle. SLIRP signature is larger than AR gene signature and is 
independent of DHT.   
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Figure 3.4: SLIRP knockdown alters cell cycle regulators enhancing cell proliferation. 
(A). p-Rb protein levels increase with SLIRP knockdown compared to NS control in LNCaP 
cells. (B) Cell proliferation is enhanced significantly with SLIRP knockdown. Values present the 
means ± SEM (N=4). (C) mRNA levels of multiple cell cycle regulators are enhanced with 
SLIRP knockdown (40nM) and furthered increased with DHT treatment in LNCaP cells. (D) 
Flow cytometry illustrates increased cell count in S-phase with SLIRP knockdown compared to 
control in LNCaP cells.  
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Figure 3.5: SLIRP knockdown does not affect AR negative cell lines 
(A) AR positive LAPC4 cells reiterate the increased p-Rb protein levels seen in LNCaP cells. 
AR negative PC3 cells do not show increased p-Rb protein with SLIRP knockdown. RT-PCR 
C 
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validation of SLIRP knockdown shown for PC3 and DU145 cells. (B) Cell proliferation is 
moderately affected with SLIRP knockdown in AR positive LAPC4 but not in AR negative PC3 
and DU145 cells. (C) qRT-PCR of SLIRP-siRNA (40nM) shows small effect in LAPC4 with 
some cyclins/CDKs while no affect was seen in most cell cycle regulators in PC3 and DU145 
cells.   
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Figure 3.6: Co-repressor SHARP but not NCoR1 or SMRT knockdown affects cell cycle in 
LNCaP cells 
(A) Knockdown of SHARP or SMRT enhances Rb phosphorylation. SLIRP and SHARP 
knockdown has the biggest affect on p-Rb protein levels compared to NCoR1 and SMRT. 
Validation of siRNA knockdown shown by RT-PCR (B) NCoR1, SMRT, or SHARP knockdown 
does not affect cell proliferation. (C) mRNA levels of cell cycle cyclins and CDKs are 
moderately increased with SHARP knockdown.(D) Cell cycle analysis demonstrates that 
SHARP knockdown increases cell number in S-phase but not NCoR1 or SMRT knockdown. 
SHARP and SMRT affect on cell cycle is preferentially enhanced by DHT treatment. (E) 
Apoptosis analysis by Flow demonstrates a minimal increase with SLIRP but a larger increase 
with SHARP, NCoR1, and SMRT. 
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CHAPTER IV: CONCLUSIONS AND FUTURE DIRECTIONS 
 
4.1 Conclusions and Future Directions 
 
Progression of prostate cancer is from PIN to adenocarcinoma. At this stage, prostate 
cancer is localized and thus curable through surgical treatment or radiation. However, further 
progression of the cancer leads to metastatic disease and upon androgen deprivation therapy; it 
progresses to castration resistant cancer (CRPC) which is currently incurable. CRPC is 
hallmarked by reactivation of androgen receptor (AR) even in low androgen environments. 
Current therapies used in CRPC include enzalutamide and abiraterone, which are both AR 
antagonists. However, the therapeutic effect of these compounds has been shown to be limited as 
the cancer eventually progresses and causes death. Multiple mechanisms contribute to the 
progression including AR splice variants, alternative growth factors, and kinase activation. 
 Previously, we have shown that Ack1 phosphorylation of AR is as an alternative 
mechanism of AR activation in CRPC. Ack1 phosphorylation of full length or truncated AR at 
Tyr-267 and Tyr-363 enhances transcriptional activity, cell proliferation and anchorage 
independent growth of LNCaP cells [81], [submitted for publication]. Mutation of AR at Tyr-267 
and to a lesser extent, Tyr-363, to phenylalanine inhibited androgen-independent proliferation, 
did not respond to androgen treatment, and showed reduction in soft agar colony formation. 
Furthermore, Ack1 drives castration resistant xenograft tumor growth and has been shown to be 
amplified in prostate tumors [70, 81]. SLIRP, a mainly mitochondrial protein, in association with 
RNA co-regulator SRA, was identified as a co-repressor of estrogen receptor (ER) signaling 
[105]. Investigation into co-repressor SLIRP in AR signaling has added another facet to the AR-
Ack1 mechanism. We show that SLIRP associates with AR resulting in repression of AR 
transactivation. Knockdown of SLIRP enhances cell proliferation, AR dependent genes PSA and 
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hK2, and AR transactivation. Moreover, activation of AR by DHT and more importantly Ack1 
results in the dissociation of SLIRP from AR, and initiation of AR dependent signaling. This 
dissociation is dependent on the kinase domain of Ack1 and an intact ligand binding domain 
(LBD) of AR. Splice variants missing the LBD of AR is elevated in CRPC and are resistant to 
therapies that target the LBD [138]. Consequently, SLIRP’s inability to repress the truncated 
form of AR and hence regulate AR is another possible mechanism of perturbed AR signaling.  
Interestingly, we found that Tyr-267 and Tyr-363 are not the phosphorylation sites of 
Ack1 mediated SLIRP dissociation from AR when these sites were mutated. Since SLIRP does 
not contain any tyrosine residues, identifying alternative Ack1 target phosphorylation sites on 
AR or possible co-factors that interact with this complex would provide a mechanism of action 
gained in CRPC. We postulate that SLIRP is part of a larger co-repressor complex that regulates 
steroid receptor signaling. Many co-activators and co-repressors regulate AR signaling and 
include NCoR1, SMRT, SHARP, and HDACs. We have not investigated whether SLIRP has any 
HDAC function though many co-repressors including SHARP, NCoR1, and SMRT can recruit 
HDACs to regulate transcriptional activity of their targets. SHARP contains domains with 
homology to SLIRP and can bind SRA at STL7 and can recruit HDAC1 [100]. Furthermore, if 
the complex is comprised of other co-repressors, like SHARP or SMRT, there is a possibility 
that HDACs are part of the SLIRP co-repressor complex. It would also be valuable to investigate 
if any candidate HDACs also dissociate from AR upon Ack1 or DHT signaling suggesting that it 
may be part of the SLIRP co-repressor complex. NCoR1 and SMRT are well-known AR co-
repressors but other candidates should be identified by utilizing proteomics including 
quantitative isotope labeling SILAC. SILAC proteomics gives us the unique advantage of 
identifying protein interactions with and without DHT treatment by differentially labeling these 
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two treatment groups. Furthermore, generation of our Ack1 inducible cell lines (constitutively 
active or kinase dead) with the expression of epitope-tagged SLIRP, could also be utilized in our 
proteomics studies.  
Furthermore, we demonstrated that compared to other AR co-repressors, SLIRP loss 
more dramatically affected cell cycle. SHARP loss also demonstrated an effect on cell cycle 
although not to the extent of SLIRP. SHARP is also a steroid receptor co-repressor that binds 
SRA and represses ER and GR activity [100, 105]. SHARP could act independently of SLIRP to 
regulate cell cycle in a mechanism similar to SLIRP. In addition, SHARP could work in concert 
with SLIRP and together regulate cell cycle. It was shown that co-transfection of SLIRP and 
SHARP resulted in reduced ER reporter activity [105]. The data implies that SHARP could be a 
good candidate as a co-repressor that is part of a SLIRP complex which acts to augment the role 
of SLIRP in AR signaling and/or cell cycle. Further interaction studies to understand if SHARP 
is also lost with Ack1 or DHT activation of AR could substantiate the hypothesis that SLIRP and 
SHARP could be working together to regulate both AR signaling and cell cycle regulation.  
 We show that SRA is important in SLIRP mediated repression of AR signaling as 
interaction of SLIRP with AR is reduced when SRA is knockdown. We found that interaction 
between AR and SRA is unchanged with heregulin or Ack1 and slightly increased with DHT 
treatment. SRA was initially identified as a co-activator that associates with another co-activator, 
SRC-1 [103]. Therefore, it is possible that SLIRP dissociates with AR activation but SRA stays 
bound to AR and helps recruit co-activators. Furthermore, there is uncertainty in the domains 
involved in binding interactions between SLIRP and AR. We show that the LBD of AR is 
needed for SLIRP association providing evidence that the co-repressor complex may bind to this 
region of AR. Using 2-hybrid and deletion studies we could define whether there is a direct or 
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indirect interaction between SLIRP, AR, and SRA. The evidence provided hypothesizes that 
SLIRP interacts indirectly with AR via SRA. Thus, binding between SRA and AR maybe more 
appropriate to investigate. 
 The gene expression studies demonstrated that SLIRP functions in multiple 
pathways and AR regulation is only a small part of what SLIRP acts upon. Compared to our AR 
gene signature of 176 genes, generation of a SLIRP gene signature found that over 1700 genes 
were affected, revealing the global affect of SLIRP knockdown. Many of the up-regulated genes 
function in cell division and DNA replication and repair, establishing a possible role of SLIRP 
not only as a steroid receptor co-repressor but a regulator of cell cycle and growth. Since we 
observed a large set of genes functioned in cell division, we investigated the cell cycle pathway. 
We found that SLIRP loss results in increased Rb phosphorylation, increased cells in S-phase, 
and increased cyclin/CDK levels in LNCaP and LAPC4 cells. The data illustrates a dose 
dependent effect in LNCaP cells on Rb phosphorylation with a higher concentration of DHT 
(10nM) inducing hypophosphorylation of Rb and reduced mRNA levels of cyclins and CDKs. It 
has previously been noted that the LNCaP cell line has a biphasic response to androgens where 
high concentrations inhibit proliferation and induce differentiation [135, 136, 139]. 
Retinoblastoma interacts with E2F-1 transcription factor resulting in inhibition of E2F activity. It 
has previously been observed that at low doses of synthetic androgen R1881, there is enhanced 
phosphorylation, increased E2F-1 levels, and increased E2F-1 mediated gene products like 
cyclin A [135]. However, at higher concentrations of R1881, Rb is hypophosphorylated and 
E2F-1 levels are decreased inferring the biphasic response of androgen on cell proliferation is 
regulated by E2F-1 activity [135]. The biphasic response may be the result of up-regulation of 
cyclin dependent kinase inhibitor (CDKI) p27/Kip1 which leads to hypophosphorylated Rb and 
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reduced E2F levels [135]. To determine the role of SLIRP in cell cycle, we could examine if 
CDKIs like p27/Kip1 are reduced with the loss of SLIRP. 
Potentially, SLIRP could regulate cell cycle by regulating the expression of G1 cyclins 
and CDKs. Most of the G1 family of cyclins that are important in phosphorylating and 
deactivating Rb, do not change at the mRNA level with androgen deprivation or stimulation [57], 
but they are affected at the protein level [55, 57]. We found no difference in the mRNA levels of 
cyclin D1 and cyclin E2 and a moderate change in cyclin E1 with SLIRP knockdown. Therefore, 
we need to explore G1 cyclins and CDKs which include cyclin D1-D3, cyclin E1 and E2, and 
CDK 4, 6, and 2 at the protein level with SLIRP knockdown. SLIRP could also regulate E2F-1 
transcriptional activity and the loss of SLIRP results in the escape of E2F-1 from Rb and 
subsequent activation of cell cycle. Additionally, the loss of Rb results in increased E2F-1 
activity and recruitment to E2F-1 regulated genes like CCNA2 as well as the AR regulatory 
locus [137]. Furthermore, in Rb competent CRPC cells resistant to androgen depletion, high 
levels of E2F-1 and AR were displayed in G1 and S-phase compared to only G1 (with reduction 
at later stage of S-phase) in normal conditions [137]. We also demonstrate a large increase in 
E2F mRNA levels demonstrating the sensitivity of E2F to SLIRP loss. Thus, it would be 
important to investigate how SLIRP regulates E2F activity which could provide a mechanism by 
which SLIRP regulates cell cycle.  
 It would be central to understand the expression of SLIRP in the different stages 
of prostate cancer. Staining of prostate tissues ranging from benign hyperplasia to PIN to 
adenocarcinoma would provide information on whether SLIRP is lost in the progression of 
cancer. Our data leads to the hypothesis that SLIRP expression would be reduced or lost in 
metastatic CRPC compared to BPH and primary tumors. Recently, it was shown that 
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glucocorticoid receptor expression is enhanced when AR is inhibited with anti-androgens leading 
to therapeutic resistance [140]. Thus, it maybe worthwhile to investigate if SLIRP expression is 
lost with anti-androgens like enzalutamide compared to untreated patients as a mechanism of 
CRPC. Furthermore, generation of a stable SLIRP knockdown cell line would allow us to 
examine in vivo whether SLIRP loss could generate tumor xenografts. We had initially tried 
establishing a stable SLIRP knockdown cell line using shRNA but were unsuccessful. Though 
SLIRP loss may initially enhance proliferation as our data suggests, long-term knockdown may 
be detrimental and induce apoptosis. For instance, E2F-1 activity can induce G1-S transition 
even in quiescent cells but also induces apoptosis possibly through p53 [141, 142]. However, 
with the development of CRISPr/CAS genome editing system that uses nuclease cleavage and 
GFP FACs sorting, we should be able to generate a stable SLIRP knockdown [143].  
We identify a novel role of SLIRP in cell cycle that have yet to be demonstrated with other co-
repressors such as SHARP, NCoR1, and SMRT. SLIRP seems to be implicated in many other 
pathways besides AR inferring that SLIRP could be a major regulator of multiple pathways. The 
gene expression data also implicates cell survival and death as one of the top pathways that were 
affected with SLIRP knockdown. We found that the loss of SLIRP by siRNA did not induce 
apoptosis compared to the other AR co-repressors tested. Hence it would be valuable to 
investigate the role of SLIRP in cell survival and death as well as other major pathways that 
seem to be affected with the loss of SLIRP. Thus, SLIRP loss not only enhances cell 
proliferation but potentially enhances cell survival, cultivating an opportunity for a potential 
cancer cell. Though we found SLIRP to be at least in part dependent on AR expression, there is a 
good possibility that other pathways may be involved in SLIRP regulation of the cell cycle. 
Though little is known about SLIRP, we demonstrate that it is an important regulator of cell 
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cycle. Abnormal cell cycle is a hallmark of cancer and abnormal AR signaling is a major factor 
in prostate cancer. Therefore, not only could SLIRP function as a potential tumor suppressor that 
is lost in the transition to CRPC, it could be a very important tumor suppressor in several 
cancers. 
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CHAPTER 5: APPENDIX 
 
5.1 Appendix 
 
Fig 5.1 Microarray Gene Expression Data of SLIRP knockdown in LNCaP Cells. 
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Table 5.2: LNCaP AR Gene Signature 
 
AR gene Signature: NS- Vehicle vs. 1nM DHT 
Class 1 Class 2 Class 3 
AADAT ABHD2 HIST2H4A ACTR3 
ABCC4 ACTB HOMER2 AK2 
ACLY ATAD2 HSPA8 C19orf48 
ACSM3 ATP11B KIF23 C1orf135 
ACY1 BRCA1 KNTC1 CENPN 
ANKH BRCA2 LDHA CLGN 
ARG2 C15orf23 LYAR EDA 
BRP44 C15orf42 MCM2 ELOVL5 
C22orf9 C6orf167 MCM3 ELOVL7 
CAPNS1 C7orf68 MCM4 ELP2 
CNGB3 CCDC21 MCM6 F5 
DHCR24 CCNE2 MCM7 FAM174B 
DHCR7 CDC6 MKI67 FDFT1 
DNASE2B CENPK MLF1IP FDPS 
EIF5AL1 CEP55 MRPL32 GPR158 
FKBP1A CHEK1 MYBL2 HIST1H4C 
GRIN3A CS MYCBP2 KCNMA1 
GRINA CSE1L NCAPH KLK2 
HMGA1 DEK NCL KLK3 
HSF1 DHFR NME1 KLK4 
IPO7 DSEL NOLC1 LSS 
ISG20L2 DSG2 NUP50 METTL3 
KCNN2 DTL NUP62 MYO19 
KLKP1 E2F1 PGAM1 PGAM5 
KPNB1 E2F7 PKMYT1 POLR2G 
MCCC2 EMP2 POLE3 PPAP2A 
MGST1 ESCO2 PPIF RFX6 
NKX3-1 FADS1 PSME3 RPS6KA3 
NUP155 FAM111B PTGES3 S100A11 
PIGH FANCM RAD54L SLC4A4 
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PPAPDC1B FARSA RPA2 SLC9A2 
PRIM2 FARSB RRM2 SMPD4 
SETD6 FEN1 SELT SMPDL3A 
SGEF FKBP5 SERBP1 SREBF2 
SLC39A10 GMPS SIGMAR1 SRM 
SLC45A3 HIST1H1B STIL TAOK3 
SORD HIST1H1E SYNCRIP TMPRSS2 
ST6GALNAC1 HIST1H2AG TCF19 TMTC2 
TCTN3 HIST1H2AJ TMEM97 TUBG1 
TPD52 HIST1H2BC TUBA1C   
TRPM8 HIST1H2BO TUBB   
TUBA3D HIST1H3B UCHL5   
UAP1 HIST1H3I UNG   
  HIST1H4J WSB2   
  HIST2H2BF ZNF367   
  HIST2H3C ZWILCH   
 
Table 5.3: LNCaP- SLIRP Gene Signature 
   
Up-regulated Gene list FDR at 0.54       
Gene ID Gene ID Gene ID Gene ID Gene ID Gene ID 
AAK1 CENPF GPD2 MAPRE1 PPFIA1 SNRPD3 
ABCE1 CENPH GRB10 MARK2 PPID SNX29 
ABHD2 CENPP GSPT1 MASTL PPIF SOX4 
ABHD3 CENPQ GTSE1 MATR3 PPIG SPAG5 
ACTB CEP170 GUCY1A3 MCCC1 PPP2R1B SPC24 
ACTR3 CEP55 H2AFX MCM2 PRC1 SPC25 
ADI1 CGN H2AFY MCM3 PRDM4 SPIN1 
AFF4 CHAF1A H3F3A MCM4 PRKDC SPTLC3 
AGPAT5 CHD1 H3F3B MCM5 PRLR SRF 
AHCTF1 CHEK1 HADH MCM6 PRMT6 SRRM1 
AIF1L CHIC1 HAT1 MCM7 PRNP SSB 
AIMP2 CHORDC1 HDAC2 MCM8 PRPF40A SSR1 
AK3L1 CHRAC1 HELLS MCTP2 PRR11 SSRP1 
AKAP5 CIT HIF1AN MDC1 PRRC1 STIL 
ALAS1 CKAP2L HIGD1A MDM2 PSMA5 STIP1 
ALDH18A1 CKAP5 HIPK2 MDN1 PSMD1 STK3 
ALS2CR4 CKS1B HIRIP3 MED29 PSME3 STMN1 
AMACR CLDND1 HIST1H1B MELK PSPC1 SUCLG1 
ANKHD1-
EIF4EBP3 CLSPN HIST1H1C METTL9 PTCD3 SUDS3 
ANKRD12 COPS3 HIST1H1E MGA PTEN SUMF1 
ANKRD52 CORO1C HIST1H2AE MIPEP PTGES3 SUMO2 
ANLN CP110 HIST1H2AG MKI67 PTGFR SUPT16H 
ANO6 CPNE3 HIST1H2AH MKI67IP PTMA SURF6 
ANP32B CPT1A HIST1H2AJ MLF1IP PTP4A1 SUV39H2 
ANP32E CREB3L2 HIST1H2AL MLH1 PTP4A2 SYNCRIP 
AP1G1 CSDA HIST1H2AM MLLT6 PTPN1 SYNE2 
AP3D1 CSDE1 HIST1H2BC MMP16 PTPN13 SYNGR2 
AP3S2 CSE1L HIST1H2BD MND1 PTPRJ SYNJ1 
APEH CSRP1 HIST1H2BF MPHOSPH9 PTTG1 TACC1 
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APOBEC3B CTPS HIST1H2BM MPRIP RAB23 TACC3 
AQR CTR9 HIST1H2BN MRPL16 RAB8B TAF15 
ARFGEF1 CYLD HIST1H2BO MRPL32 RACGAP1 TARS 
ARHGAP11A CYP51A1 HIST1H3B MRPL4 RAD21 TBC1D5 
ARHGAP19 DAPK1 HIST1H3D MRPL42 RAD51 TBCA 
ARHGAP20 DCAF16 HIST1H3I MRPL49 RAD51AP1 TCEAL4 
ARHGAP28 DCAF5 HIST2H2AA3 MRPS17 RAD51C TCF19 
ARIH2 DCP1A HIST2H2AC MSH6 RAD54L TCOF1 
ARL5B DDX10 HIST2H2BF MTA2 RAD54L2 TCP1 
ARL6IP1 DDX19A HIST2H3C MTFR1 RAI14 TCTE3 
ARL8B DDX21 HIST2H4A MTHFD1 RANBP1 TDG 
ARMCX5 DDX27 HMGB1 MTMR12 RANGAP1 TEAD1 
ARNT DDX39 HMGB2 MUT RAP2B TGM3 
ARPC5 DDX3X HMGCS1 MVK RBBP8 THBS1 
ARPP19 DDX46 HMGN1 MYBL2 RBM25 THOC4 
ASCC3 DDX5 HMGN2 MYCBP2 RBM28 THRB 
ASF1B DEK HMGN5 MYL12A RBM3 TIMELESS 
ASPM DENND1B HMMR MYNN RBM8A TJP1 
ATAD2 DENND4C HN1 MYO6 RC3H2 TLE3 
ATAD5 DENR HNRNPA1 NAA15 RCC2 TM9SF2 
ATIC DEPDC1 HNRNPA1L2 NAA50 RCN2 TMEM109 
ATP11B DEPDC1B HNRNPA2B1 NANP RELL1 TMEM144 
ATP13A3 DHFR HNRNPA3 NAP1L1 REV3L TMEM170A 
ATPAF1 DIABLO HNRNPAB NAPEPLD RFC2 TMEM2 
ATPIF1 DIAPH1 HNRNPC NASP RFC4 TMEM30A 
ATXN1L DIAPH3 HNRNPD NBEAL2 RFXAP TMEM97 
AURKB DICER1 HNRNPF NBPF15 RG9MTD1 TMPO 
BAG3 DKC1 HNRNPH1 NCAPD2 RHEB TOB1 
BAG5 DLGAP5 HNRNPH3 NCAPD3 RHOB TOP2A 
BAZ1A DNA2 HNRNPM NCAPG RIF1 TOPBP1 
BAZ1B DNAJC11 HNRNPR NCAPG2 RIMKLA TOX3 
BAZ2A DNAJC8 HNRNPUL2 NCAPH RIT1 TP53I11 
BBS10 DNAJC9 HNRPDL NCKIPSD RNF168 TP53INP1 
BCL6 DNMT1 HSDL1 NCL RNF26 TPM3 
BIRC5 DOT1L HSP90AB1 NCS1 RNF43 TPM4 
BLM DPH5 HSP90AB2P NDC80 RPA2 TPRKB 
BNIP2 DRAP1 HSPA4 NDUFS5 RPF1 TPT1 
BRCA1 DSEL HSPA8 NEDD4L RPF2 TPX2 
BRCA2 DSG2 HSPE1 NEK2 RPL11 TRA2B 
BRIP1 DSN1 HTATSF1 NEK7 RPL22 TRAPPC1 
BRIX1 DTL IDI1 NF2 RPL22L1 TRIM37 
BRWD1 DTYMK IGF2R NFATC2IP RPL23 TRIP13 
BTG2 DUSP3 IL6R NFKBIL2 RPL23AP53 TTF2 
BUB1 DVL3 ILF2 NIPBL RPL23P8 TTK 
C10orf12 DYNC1LI2 IMPDH2 NME1 RPL26 TUBA1A 
C11orf57 DYNLT3 INCENP NOLC1 RPL28 TUBA1B 
C12orf11 DYRK2 INSIG1 NOP14 RPL36A TUBA1C 
C12orf23 E2F1 IQGAP3 NOP2 RPL38 TUBA4A 
C12orf48 E2F2 ISY1 NPM1 RPL7L1 TUBB 
C13orf23 E2F7 ITGB1 NRAS RPS15A TUBB2C 
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C14orf106 ECT2 ITSN2 NRIP1 RPS17 TUBB3 
C15orf23 EFNA5 JMJD1C NSUN2 RPS2 TUFT1 
C15orf42 EFNB2 KANK2 NUDT15 RPS24 TUG1 
C15orf44 EIF2C2 KATNAL1 NUDT9 RPS26 TULP4 
C18orf32 EIF3G KBTBD6 NUF2 RPS26P11 TYMS 
C1QBP EIF3M KCTD2 NUP107 RPS4X TYW3 
C22orf46 EIF4A1 KCTD5 NUP210 RPS6KA2 U2AF2 
C4orf46 EIF4B KCTD9 NUP50 RPS6KA4 UACA 
C5orf34 EIF4EBP1 KIAA0020 NUP88 RPS6KB1 UBA2 
C6orf167 EIF4G1 KIAA0101 NUP93 RRM1 UBE2C 
C9orf100 EIF4G2 KIAA0114 NUP98 RRM2 UBE2E2 
C9orf5 EIF5B KIAA0182 NUSAP1 RRN3 UBE2G2 
C9orf86 ELAVL1 KIAA0247 ODC1 RSL1D1 UBE2N 
CACYBP EMP2 KIAA0947 ODF2 RTKN2 UBE2R2 
CALM1 ENDOD1 KIAA1033 OGDH S100PBP UBE2T 
CAMK2N1 EPB41L4B KIAA1524 OLA1 SACM1L UBR7 
CAMSAP1 EPCAM KIF11 ORC1L SACS UBXN2B 
CAP1 ERBB3 KIF14 ORC6L SAFB UCHL5 
CARHSP1 ERCC6L KIF15 OSBPL8 SAFB2 UCK2 
CASC5 ERI1 KIF18B OTUD3 SARNP UGGT1 
CASD1 ESCO2 KIF20A OXCT1 SART1 UHRF1 
CASP7 EXO1 KIF20B PA2G4 SASS6 UQCRFS1 
CBLN2 EZH2 KIF21A PA2G4P4 SBDS USP15 
CBWD2 FADS1 KIF23 PABPC1 SCLY USP22 
CBX5 FAM111B KIF24 PABPC3 SDC1 USP38 
CBX6 FAM123B KIF2C PABPC4 SDCCAG3 USP45 
CCDC117 FAM126B KIF4A PAK2 SEC63 USP47 
CCDC14 FAM178A KIFC1 PAPD7 SELT VAMP7 
CCDC15 FAM190B KLHL8 PARP1 SEMA3C VANGL1 
CCDC18 FAM35A KLK3 PARP2 SENP1 VARS 
CCDC21 FAM45A KNTC1 PBK SEP11 VPS36 
CCDC59 FAM45B KPNA1 PCM1 SEPN1 VPS4B 
CCDC86 FAM54A KPNA2 PCNA SERBP1 WDHD1 
CCDC99 FAM55C L2HGDH PDCD11 SERTAD2 WDR62 
CCNA2 FAM72A LAD1 PDCD2 SET WDR67 
CCNB1 FANCD2 LARP4 PDCD4 SETD8 WDR76 
CCNB2 FANCI LASS6 PDCD5 SF3B2 WDR82 
CCNE1 FARSA LCLAT1 PDE7A SFPQ WEE1 
CCNE2 FASTKD5 LDHA PDLIM5 SFRS1 WHSC1 
CCNF FBXO5 LEMD3 PDXDC1 SFRS13A WSB2 
CCT2 FDX1 LMNB1 PEBP1 SFRS2IP WWC3 
CCT5 FEN1 LMNB2 PFKFB3 SFRS4 XPO1 
CCT6A FGFRL1 LOC100190938 PGAM1 SFRS8 XPO4 
CCT8 FIGNL1 LOC221710 PGRMC1 SFXN2 XRCC2 
CDC20 FIZ1 LOC253039 PHACTR2 SGCB XRCC5 
CDC25A FKBP5 LOC441454 PHF15 SGOL1 XRCC6 
CDC25B FOXK2 LOC644936 PHF20 SGOL2 YBX1 
CDC40 FOXM1 LOC647979 PHF6 SGPL1 YWHAB 
CDC45 FRS2 LOC649330 PHTF2 SHCBP1 YWHAG 
CDC6 FXC1 LPGAT1 PIGW SHISA5 YWHAH 
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CDC7 FXR1 LRIG3 PIM1 SIGMAR1 YY1AP1 
CDCA2 FZD6 LRPPRC PKMYT1 SKA1 ZBTB5 
CDCA3 GART LRRC58 PLAGL2 SKA3 ZC3H13 
CDCA5 GCH1 LRRC8B PLEKHB2 SLAIN2 ZIC2 
CDCA7L GCLC LRRFIP1 PLK1 SLC16A1 ZMAT2 
CDCA8 GDI2 LSM3 PLK2 SLC19A2 ZNF146 
CDCP1 GFM2 LYAR PLK4 SLC1A4 ZNF252 
CDK1 GGCT LYRM7 PLP2 SLC25A24 ZNF286A 
CDK5RAP2 GINS1 LYSMD3 PNN SLC25A36 ZNF326 
CDKN1A GINS2 MAD2L1 PNP SLC27A2 ZNF367 
CDKN3 GINS4 MAGI1 PODXL SLC39A6 ZNF460 
CDT1 GLB1 MAGOHB POLA1 SLC7A1 ZNF512B 
CDV3 GLE1 MAL2 POLD3 SLC7A6 ZNF766 
CEBPZ GM2A MAP1B POLE3 SLMO2 ZWILCH 
CECR5 GMPS MAP3K3 POLQ SLTM ZWINT 
CELF1 GNB4 MAP3K9 POLR1B SMARCC1   
CENPA GNG10 MAP4K4 POLR2B SMC1A   
CENPB GNG5 MAPK1IP1L POTEE SMCR7L   
CENPE GOLIM4 MAPK8IP2 PPAT SNRPD1   
 
Table 5.3: LNCaP- SLIRP Gene Signature 
  
Down-regulated Gene list FDR at 4.59     
Gene ID Gene ID Gene ID Gene ID Gene ID Gene ID 
ABAT COMT HDLBP MYH10 RAB6A STAU2 
ABCA2 COPB1 HEATR5A MYH9 RAB6C STEAP1 
ACAD10 COPE HECTD1 MYO1D RABEP2 STEAP2 
ACADSB COPG HERC3 MYO5A RABL3 STK38L 
ACBD3 COPZ1 HERC5 MYO5B RAC1 STT3B 
ACBD6 CORO2A HERC6 NAALADL2 RAD23B STX12 
ACLY COX7C HERPUD1 NACAP1 RAF1 STXBP3 
ACOX3 CPD HEXA NAPA RALGPS2 STXBP4 
ACPL2 CRELD1 HEXB NBN RAMP1 STYX 
ACPP CSAG2 HINT3 NBPF16 RANBP9 SUB1 
ACTG1 CSMD1 HIST2H2BE NBR1 RAP1GAP SUMF2 
ADAM9 CST3 HLA-B NCOA2 RARRES3 SUSD4 
ADAMTS1 CTBP2 HLA-C NCRNA00182 RASEF SUV420H1 
ADAP1 CTBS HNRNPUL1 NCSTN RBM47 SYNGAP1 
ADAR CTNNB1 HOXB13 NDFIP1 RBM7 SYNJ2BP 
ADCK4 CTSB HPN NDUFA1 RCN1 TAB2 
ADM2 CTSF HSP90AA1 NDUFA4 RDH11 TAB3 
AES CTSH HSP90B1 NDUFB4 REEP5 TACC2 
AFF1 CTSO HSPA1B NECAB3 RELN TAPBP 
AGBL5 CTTN HSPA5 NEIL2 RFNG TBC1D14 
AGPAT6 CYB5R3 IDH3G NEK9 RG9MTD2 TBC1D4 
AGRN DAK IDS NELF RHOQ TBL1X 
AKR1A1 DAP IFI27 NEO1 RHOU TCF12 
AKTIP DAZAP2 IFI44 NFIA RIMS1 TCIRG1 
ALDH6A1 DCAF12 IFI6 NIPAL2 RMND5A TERC 
ALDOA DCTN4 IFIT1 NIPSNAP3A RMRP TES 
ALDOC DCUN1D4 IFIT2 NKX3-1 RNF10 TESK2 
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ALKBH5 DDIT4 IFIT3 NLRX1 RNF11 TGFBR1 
ALOX15 DDX17 IFITM1 NME3 RNF14 TGFBR3 
ALS2CR8 DDX18 IFITM3 NME5 RNF170 TM7SF2 
ANAPC16 DDX58 IGSF3 NOP10 RNF187 TM9SF3 
ANGEL1 DDX60 IKZF5 NOTCH3 RNF213 TMBIM4 
ANK3 DEAF1 IL13RA1 NPDC1 RNF215 TMBIM6 
ANKH DEGS1 IL17RD NQO1 RNF31 TMC4 
ANKRD40 DHCR24 IL1RAP NQO2 RNF41 TMED10 
AP1S3 DHX40 IL6ST NR2F6 ROCK1 TMED2 
AP2B1 DIDO1 IMPA1 NRBP2 ROCK2 TMED7 
APP DIMT1L IMPACT NSMCE1 RPL13AP6 TMEFF2 
AR DIRC2 INPP5A NT5DC2 RPL29 TMEM106B 
ARFGAP3 DLG5 INSR NTN4 RPL3 TMEM123 
ARHGAP18 DNAJC24 IPO7 NUCB1 RPL36 TMEM129 
ARHGAP5 DNAJC3 IRF2BP2 NUCB2 RPL37A TMEM132A 
ARHGEF9 DNAJC4 IRF7 NUCKS1 RPL39 TMEM14A 
ARL2BP DNAJC5 IRF9 NUDT22 RPL41 TMEM159 
ARMCX3 DPY19L4 ISG15 NUDT8 RPL9 TMEM209 
ASAP2 DR1 ITGA2 NUMA1 RPN2 TMEM38B 
ASH1L DTWD2 ITGA5 NUMBL RPPH1 TMEM40 
ATF6 DUSP16 ITGAV NUPL1 RPRD1A TMEM54 
ATG2B EDEM3 ITPR1 NUS1 RPS12 TMEM59 
ATP11A EEF1A1 IYD NXT2 RPS19 TMEM63B 
ATP11C EEF1A1P9 JUND OAS1 RPS27 TMEM66 
ATP1B1 EFHC2 KCNN2 OAS2 RPS9 TMEM8B 
ATP2B1 EFR3A KCNQ1 OASL RRAS2 TMEM98 
ATP2C1 EGFL7 KCTD3 OAZ1 RRBP1 TMTC3 
ATP5A1 EGLN1 KDELR1 OCLN RSAD2 TMTC4 
BAIAP2 EHBP1 KDELR2 OCRL RSPRY1 TNK2 
BCAM EI24 KDM5C OGFOD2 RTF1 TNRC6B 
BCL10 EIF2AK2 KDM6A OPLAH RWDD4A TOB2 
BCL2L1 EIF2S1 KEAP1 OPTN RYR2 TOM1L1 
BLZF1 EIF5A KIAA0232 ORAI3 SALL2 TOMM34 
BNIP3 EIF5AL1 KIAA0319L ORMDL3 SAP30L TOP2B 
BOD1 ELK3 KIAA0494 OSBP SASH1 TPD52 
BSCL2 EMB KIAA1143 P4HB SAT1 TPM1 
BSDC1 ENAH KIAA2018 PACS1 SBF2 TRAM1 
BST2 ENOPH1 KIF3B PAICS SC5DL TRIM44 
BTBD7 ENOX2 KIF5B PALLD SCARB2 TSEN34 
BTD ENTPD3 KIFAP3 PAN3 SCARNA2 TSPAN1 
BTF3L4 EPB41 KLF3 PANK3 SCD TSPAN3 
BTN3A3 EPHX2 KLHL12 PAPD4 SEC13 TSPAN31 
BZW1 EPS15 KLHL15 PARK7 SEC24C TSPO 
C10orf18 ERBB2 KLHL20 PARP11 SEC61A1 TSPYL1 
C10orf32 ERGIC3 KREMEN1 PBX1 SEC61B TTC3 
C10orf57 ESYT1 KRT6C PCDH11X SEL1L3 TWF1 
C11orf54 ETNK1 KRT8 PCDH11Y SELENBP1 TWSG1 
C11orf71 F8A1 KRTCAP3 PCIF1 SEP15 TXNDC5 
C14orf156 FAAH LAMA5 PCMTD2 SEPP1 TXNIP 
C14orf159 FADS2 LAMB2 PDE10A SERF2 UBA7 
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C15orf17 FAM108B1 LASS2 PDE12 SERINC3 UBE2E1 
C16orf58 FAM114A1 LATS1 PDE3B SERINC5 UBE3C 
C17orf101 FAM120A LBR PDIA3 SESN1 UBFD1 
C17orf28 FAM134B LGALS3BP PDIA3P SETD7 UHMK1 
C17orf71 FAM134C LGMN PDIA4 SETDB1 UNC93B1 
C17orf95 FAM135A LIFR PDIA6 SEZ6L2 UQCRQ 
C19orf22 FAM173A LIN7C PDXDC2 SF3B1 USP33 
C19orf63 FAM198B LLGL1 PDZD8 SFRS9 USP46 
C19orf66 FAM199X LMAN1 PEA15 SGEF USP54 
C1orf113 FAM21C LMAN2 PECI SGSM3 VAMP2 
C1orf43 FAM38A LOC285074 PEX10 SH3D19 VAMP3 
C1orf53 FAM73A LOC339047 PEX19 SH3RF1 VASP 
C1orf58 FAM84B LOC651250 PFKM SHANK3 VBP1 
C20orf112 FBXL17 LPHN1 PGAP2 SHROOM2 VCP 
C3orf23 FBXO28 LRP1 PHF12 SI VGLL4 
C4orf3 FBXO3 LRP10 PIAS3 SIK1 VPS37C 
C4orf34 FBXO9 LRP8 PICALM SIK2 VPS53 
C4orf48 FBXW4 LRPAP1 PIK3CB SLC12A7 VTA1 
C5orf15 FEM1B LRRC59 PIKFYVE SLC16A7 WASF3 
C5orf30 FEZ2 LRRN1 PITPNA SLC17A5 WASL 
C5orf51 FEZF2 LTBP3 PKD2 SLC22A23 WDR11 
C6orf120 FKBP10 LUZP6 PL-5283 SLC22A5 WDR18 
C6orf162 FKBP11 LY6E PLA2G12A SLC25A16 WDR3 
C6orf211 FKBP1A LYPLA1 PLDN SLC25A17 WDR72 
C6orf64 FKBP8 LYRM5 PLEKHA1 SLC25A23 WDTC1 
C7orf63 FLOT2 MAGEA10 PLIN3 SLC25A39 WIPF2 
CALR FNBP1L MAGED1 PNPLA7 SLC2A4RG WIPI2 
CALU FNDC3A MALT1 PODXL2 SLC30A4 WWP1 
CAPN1 FOLH1 MAN2B1 POMGNT1 SLC30A7 XAF1 
CAPN7 FOSL2 MANBAL PPA2 SLC30A9 XIAP 
CASC4 FTL MANEA PPAP2B SLC31A1 XRN2 
CBX3 FUCA1 MAP2K2 PPAPDC1B SLC35A1 YOD1 
CCDC113 GABARAP MAP2K3 PPCS SLC35B1 YWHAE 
CCDC125 GALK1 MAPKSP1 PPFIA2 SLC35F5 YWHAZ 
CCDC6 GALNT1 MARCKS PPIB SLC37A4 ZBTB10 
CCDC90B GANAB MAST4 PPIL4 SLC38A10 ZBTB20 
CCNI GAPVD1 MAT2B PPM1K SLC38A2 ZBTB41 
CD151 GBP3 MB PPM1M SLC39A10 ZBTB44 
CD164 GCC2 MCL1 PPP1R2 SLC7A11 ZC3H12A 
CD63 GCNT2 MCRS1 PPP2R1A SMG5 ZCCHC14 
CD81 GFPT1 ME1 PPP2R4 SMPD1 ZFAND5 
CD82 GGT1 MED13 PPP2R5A SND1 ZFYVE20 
CDH1 GLG1 MED16 PPT1 SNORA63 ZFYVE9 
CDH15 GLT8D1 MED21 PRAME SNRK ZG16B 
CDK16 GNA14 MEGF8 PRDX1 SNRPN ZHX1 
CDK19 GNB2 METRN PRDX2 SNX1 ZHX2 
CDS2 GNG7 MFAP3 PRIC285 SNX17 ZMYM2 
CELSR1 GNPNAT1 MFSD10 PRKAA2 SNX25 ZMYND11 
CELSR2 GOLGA1 MFSD11 PRKACB SNX9 ZNF107 
CFB GOLGA5 MFSD3 PRKAR2A SORL1 ZNF117 
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CFL2 GPAA1 MID1IP1 ProSAPiP1 SP100 ZNF16 
CHD3 GPER MKL2 PRR7 SPATA13 ZNF253 
CHD6 GPR107 MKLN1 PSAP SPATA20 ZNF254 
CHML GPR126 MLEC PSAT1 SPATS2 ZNF268 
CHMP6 GPR137B MMD PSD4 SPINT2 ZNF33B 
CHP GPR155 MME PTK2 SPON2 ZNF385A 
CHPF GPR180 MMGT1 PTOV1 SPTBN2 ZNF414 
CHURC1 GPRC5B MOBKL3 PTPN11 SPTLC1 ZNF462 
CIRBP GPRC5C MON2 PTPRF SPTLC2 ZNF471 
CLCN3 GRLF1 MOSPD2 PTPRS SQRDL ZNF493 
CLDN12 GRPEL2 MRPL18 QARS SQSTM1 ZNF664 
CLIC4 GRTP1 MRPL34 QKI SRP9 ZNF678 
CLPB GSTA4 MSI2 QSER1 SSH3 ZNF703 
CMBL GTF2I MTHFR RAB12 SSR2 ZNF708 
CMPK2 GUK1 MTMR2 RAB18 SSR3 ZNF714 
CMTM4 GULP1 MTMR6 RAB2A SSR4 ZNF737 
CNBP H2AFV MTMR9 RAB37 STAG3L4 ZNF91 
COL18A1 H6PD MTUS1 RAB3B STAT1 ZYX 
COMMD10 HCG2P7 MXD4 RAB5A STAU1   
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